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Dynamic prediction of survival data using single or multiple longitudinal markers
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Recurrent events and time-to-event data occur frequently in longitudinal studies. In
large clinical trials with survival endpoints, researchers collect a multitude of longitudinal
markers. There is a growing need to utilize these rich longitudinal information to build
prediction models and assess their prognostic performance. In this dissertation research,
I propose a novel approach of integrating longitudinal markers in modeling the recurrent
event or terminal event data, and conduct dynamic prediction of event risks. Under
joint a model framework, I jointly model a longitudinal outcome and a recurrent event
process with the two process correlated via shared latent function. The probability of
having a new occurrence of recurrent event in a given time interval is predicted based on
subject-specific longitudinal profile and disease history. When multivariate longitudinal
outcomes are considered, traditional joint model method has limitation on specifying appropriate longitudinal structures and computation problem occur when using Bayesian
approach. To avoid these potential issues, I employ multivariate functional principal
component analysis approach which is more flexible, robust and time efficient. For ter-

minal event data, I specify a prognostic model incorporating multivariate longitudinal
information, the prediction can be updated with accumulated data over time. I also
propose a recurrent event model integrating multiple longitudinal markers and conduct
personalized dynamic prediction of new recurrent event risk, which helps physicians to
identify patients at risk and give personalized health care.
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Chapter 1

Background

1

1.1
1.1.1

Literature Review
Cardiovascular disease

Cardiovascular disease (CVD), a leading cause of death and disability in both men and
women worldwide, causes one in every four deaths in United States and has raised a
major public health concern[1]. The estimated annual costs for CVD reached 207 billion
dollars in health care area in the United States [2]. Understanding the risk factors for
CVD yields important insights into prevention, treatment and prediction of disease progression. To this regard, numerous clinical studies were funded by National Heart, Lung,
and Blood Institute (NHLBI) aiming to identify risk factors for predicting future CVD
events and further more, to develop and assess performance of different risk prediction
models. For instance, NHLBI has sponsored Anti-hypertensive and Lipid-lowing Treatment to Prevent Heart Attack Trial (ALLHAT) study [3], Cohorts for Heart and Aging
Research in Genomic Epidemiology (CHARGE) consortium which includes 3 studies:
Framingham Heart Study (FHS), Cardiovascular Health Study (CHS), and Atherosclerosis Risk in Communities (ARIC) [4]. Despite having different Cardiovascular disease
as study outcome, there are commonality among the aforementioned 4 clinical trials: (1)
Study participants with higher risk may experience several cardiovascular events including coronary heart disease (CHD), stroke, and heart failure during the whole study. These
events occur repeatedly during their follow-up time and are correlated to each other, gen-
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erating recurrent event outcome; (2) longitudinal biomarkers of participants are available
in scheduled visits during their follow-up time, including systolic blood pressure, total
cholesterol which were proved to be predictive in cardiovascular disease events [5, 6].
Regardless of numerous research on inference or prediction of the survival risk in cardiovascular disease area, these studies either employ simple survival models or logistic
models that fail to utilize the complete longitudinal health outcome trajectories that are
predictive of CVD, or fail to account for the recurrent nature of the CV event occurrence. Alternatively, leveraging frequently measured longitudinal health biomarkers and
survival outcome, we propose to develop a personalized dynamic prediction model using
these CVD study datasets. Our proposed model not only provides more accurate personalized predictions but also is able to dynamically update the prediction results upon
the availability of updated subject-specific data in new visits.

1.1.2

Parkinson’s disease

Parkinson’s disease (PD) is a chronic progressive neurodegenerative disorder manifested
as tremor, rigidity, slow movement, and impaired balance in clinics, affecting about 1%
of adults older than 60 years. PD is caused by the malfunction and death of neurons,
which are the nerve cells in the brain. Part of the the malfunctioned and dying neurons
produce dopamine, which is a chemical that helps control movement and coordination of
human body.
Previous literature studied a broad range of motor and non-motor symptoms which
3

are clinically correlated with evolution of Parkinson’s disease [7–9]. However, due to
substantial heterogeneity of different symptoms and subjects, it is very challenging to
give accurate prognoses of disease progression. In the absence of a cure, there is a critical
need to identify significant and well-validated biomarkers associated with PD progression
[10]. As a complex progressive disease, a variety of endpoints have been established to
evaluate PD severity and work as a criteria to categorize subjects into different disease
stages. For example, Unified PD Rating Scale (UPDRS), modified Hoehn and Yahr (HY)
scale, and Ambulatory capacity evaluate patients’ movement ability [11, 12]. Among
these measures, Hoehn and Yahr (H&Y) scale has became one of the most commonly
and widely used measurement to assess overall PD dysfunction stage [13]. Schrag et
al. [14] examined the responsiveness of different PD progression outcome measures over
time and suggested the H&Y scale to be the most responsive measure. Based on motor
functions, the H&Y scale has served as a good endpoint of PD progression in many
published studies. The time to development of different H&Y stages from symptom
onset or enrollment has been widely studied as a way to evaluate disease progression in
past literature [15–18]. Although these literature discussed potential prognostic factors
in predicting the H&Y stage progression, only baseline variables were included in the
survival model and longitudinal information was not taken into account. Relatively few
studies considered modelling longitudinal marker in prediction of PD disease outcome. He
and Luo [19] proposed a joint model with multilevel item response theory sub-model for
the longitudinal data and Cox propotional hazard sub-model to handle time to terminal
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event. They assessed the effect of tocopherol on time to initiation of symptomatic therapy
in early PD patients. Iddi et al. [20] applied a latent time joint mixed-effects model to
handle longitudinal outcomes and studied the association between different markers and
PD diagnostic category. However, to our best knowledge, no previous research has been
done regarding prognostication of time to the H&Y stage transition based on multiple
longitudinal markers.

1.1.3

Recurrent Event Data Analysis

Many disease and clinical study outcomes may reoccur in the same participant, which
makes the investigation of multiple time-to-event data for one subject important. Examples of recurrent events include recurrent strokes in elderly patients, recurrent heart
failure, and recurrent heart attack [21]. An important feature of these events is that
there exists intrinsic correlation between those repeated occurrences within the same
subject. Ignoring this unique feature of correlation of recurrent events, the estimated
event occurrence rates could be biased [21]. Hence, the most commonly used Cox proportional hazard model in biostatistics and epidemiological field will not be appropriate
here, because they do not consider the correlation of the repeated occurrences.
Numerous researchers have conducted statistical research in recurrent event data analysis field. Vaida and Xu [22] proposed a general proportional hazards model with random effects for handling clustered recurrent event data. Pepe and Cai [23] have proposed
semi-parametric procedures for making inferences about the mean and rate function of
5

the counting process without the Poisson-type assumption . An approach to constructing
simultaneous confidence bands for the mean function was presented by Lin et al. [24].
Recurrent event data has two important features. One is that the recurrent events
are ordered (the second event can only occur after the first event), while another feature
is that the subject can only be at risk for one event at a time (i.e. within a small time
interval ∆t, only one event can happen) [21]. A common approach to model the recurrent
event data is to assume that the event process is poisson process so that the number of
events in disjoint time intervals is assumed to be independent [25]. The key aspect of
analyzing recurrent event data is to model the intensity function. Poisson process models
intensity function as a function of calender time. Assuming that n events occur in time
interval [0,τ ], we denote the event times as t1 , t2 , ...tn−1 , tn ≤ τ . Therefore, the total
number of events up to time t is N (t), t > 0. Let H(t) = {N (s) : 0 ≤ s < t} denote the
event process history and information on the covariate process up to time t, we can write
the intensity function of the process λ(t, Hi ) as below:

P r{N (t + ∆t− ) − N (t− ) = 1}
P r{∆N (t) = 1 | Hi (t)}
= lim
, (1.1)
∆t→0
∆t→0
∆t
∆t

λ(t|Hi (t)) = lim

where ∆N (t) denotes the number of events over a small interval [t, t + ∆t). Denoting
λ(t|Hi (t)) = λi (t), the likelihood contribution from each subject in time period [0, τ ] can
be written as :
"n
i
Y

#

 Z
λi (tj ) × exp −
0

j=1
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τ


λi (t)dt .

(1.2)

1.1.4

Overview of Dynamic Prediction via Joint Models

Joint models (JM) of longitudinal measurements and survival data have been widely
studied in the past two decades (first proposed by Faucett & Thomas [26] and Wulfsohn
& Tsiatis [27]), there is an increasing number of literature investigated the application
of joint models to large clinical studies, e.g., Henderson et al. [28], Han et al. [29] and
Crowther et al. [30]. Usually, a joint model involves two sub-models, one is a mixed effects model for longitudinal outcomes while the other is a Cox model for survival events.
To link the two sub-models together, shared random effects are usually utilized. Previous
literature have compared and investigated the association structure for random effects
[31]. For inference purpose, joint models can be used to estimate the parameters associated with the longitudinal models as well as the survival models. Although there exists
many literature discussing joint model of longitudinal markers and time-to-event data,
few studies has investigated the joint model of longitudinal markers and recurrent event
data. Henderson [28] proposed a joint model of longitudinal data and recurrent event
data, with association between two process captured by correlated latent trajectory. Liu
and Huang [32] established a JM approach where a more complex setting was considered,
i.e. a repeated measures process and a recurrent events process were correlated, both
subject to a terminal event. In addition to model inference, a novel usage of JM is to
provide dynamic prediction of the risk of target event and the trajectories of biomarkers.
Rizopoulos [33] has proposed a Monte Carlo approach to conduct dynamic prediction
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on time-to-event data, which predicts subject-specific survival probability using the joint
model framework. The key feature of the dynamic prediction framework is that the
prediction can always be dynamically updated given the additional information of longitudinal trajectories and longer history of survival process. There are some literature
of the dynamic prediction problem under joint model of longitudinal and survival data
framework [34, 35]. Regarding the prediction for recurrent event data, Krol et al [36]
extended the usage of joint model to include recurrent event process, and estimated the
probability of having a terminal event in specific time interval, given historical longitudinal data and recurrent event times. An alternative approach was proposed by Musoro
et al [37] by employing landmark method to handle the longitudinal data as time-fixed
covariate at different landmark time points, the dynamic prediction by landmarking was
then extended to recurrent event data in this way. However, to our best knowledge,
providing personalized dynamic prediction of recurrent events by joint model method
remains an open question. To propose a prediction model that incorporates clinical information and the recurrent disease history is of importance here. In this dissertation, we
develop a Bayesian joint model which consist of two sub-models, one is the linear mixed
effect model to model longitudinal trajectory, another is recurrent event model with intensity function from Poisson process to handle the recurrent event process. The dynamic
prediction of recurrent events is derived and implemented in application datasets.

8

1.1.5

Multivariate Principal Component Analysis

In most literature, dynamic predictions via joint models have been restricted to only include single longitudinal outcome. However, emerging evidence has suggested that many
diseases are correlated with multiple longitudinal clinical outcomes. Moreover, in large
clinical studies, rich clinical information including observations of multiple longitudinal
biomarkers is collected. Incorporating these clinical information in prediction of event of
interest becomes an urgent need. Extending the JM approach to incorporate multivariate
longitudinal outcomes has a major limitation that we need to specify appropriate parameter distributions and correlation structure between longitudinal processes. In addition,
the computation intensity is another concern when utilizing joint model under Bayesian
framework, especially with large sample size. As the number of candidate longitudinal
markers increase, the computation cost increases exponentially. To handle the multivariate longitudinal outcomes and avoid involving in the aforementioned issues, we consider
an alternative approach which is more flexible, robust and computationally efficient. Yao
[38] first proposed a nonparametric approach to perform functional principal components
analysis (FPCA) on sparse longitudinal data. Since then, researchers has extended the
usage of FPCA to joint analysis of repeated measurements and survival data [39]. In
the two-step approach proposed by Holte et al [40], the feature of longitudinal trajectory was extracted and represented by the functional principal component (FPC) scores
estimated from separate model in step one, and the estimated FPC scores were included
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in the survival model as new risk factors to build association between longitudinal trajectory and the survival outcome. In regards of prediction, Yan et al [41] extended the
FPCA framework further to dynamic prediction area. Their work updates the estimated
FPCA scores as new longitudinal information come into available. However, these studies
only incorporated a single longitudinal marker in the survival model. Moreover, the Cox
model they used to model the terminal event is not suitable when the event of interest
has recurrent feature (e.g. CVD events). To our best knowledge, there is no existing
literature has investigated the prediction of recurrent event utilizing information from
multiple longitudinal markers. In this dissertation work, we develop an novel approach
to fit this critical need.

1.2

Public Health Significance

Even with the contemporary medical techniques nowadays, cardiovascular disease still
acts as a leading cause of death and disability in both men and women in United States
and worldwide. It causes one in every four deaths and has became a major public health
concern. Investigation in risk factors is a key step to cardiovascular disease treatment
and prevention. There is strong evidence suggesting that persons with healthier lifestyle
could significantly reduce the risk of incidence in cardiovascular events (e.g. quit smoking,
avoiding obesity, exercise routinely, consume green food, and keep a healthy diet) [42].
Therefore, identifying and quantifying risk factors is of great interest in modern public
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health area.
While discovering significant and well-validated risk factors, predicting risk of the
future event is another important mission. Accurate prediction of the risk of a subject’s
future cardiovascular event in a specific given time period enables physicians to make
personalized diagnostic and treatment. Based on subject-specific longitudinal profiles
and updated event history, the proposed work can help physicians target people with
higher risk of developing a CVD events in a near future. This task helps address the
critical need for model-based personalized dynamic predictions of future longitudinal
health outcome trajectories and CVD events.

11

Chapter 2

Article 1: Dynamic prediction using joint models of
longitudinal and recurrent event data: A Bayesian
perspective
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Dynamic prediction using joint models of longitudinal and recurrent event data: A Bayesian perspective

2.1

Introduction

As a leading cause of death and disability in both men and women worldwide, cardiovascular disease (CVD) causes one in every four deaths in United States and has became a
major public health concern [1]. The estimated annual costs for CVD reached 207 billion
dollars in health care area in the United States [2]. It is of importance to understand
the risk factors for CVD which yields important insights into prevention, treatment and
prediction of disease progression. National Heart, Lung, and Blood Institute (NHLBI)
has funded many clinical studies aiming to identify risk factors for predicting future
CVD events. Anti-hypertensive and Lipid-lowing Treatment to Prevent Heart Attack
Trial (ALLHAT) study [3] is one of the largest CVD studies that sponsored by NHLBI.
Previous literatures have identified hypertension, high cholesterol level, diabetes etc. are
highly related to risk of developing cardiovascular disease [43, 44].
An important feature of cardiovascular disease is that the primary event outcomes
are often recurrent, i.e. patients can experience multiple CVD events during the followup period. Examples of these recurrent events include strokes, reoccurred heart failure,
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and recurrent heart attack [21]. An important feature of these events is that there
exists intrinsic correlation between those repeated occurrences within the same subject.
Ignoring this unique feature of correlation of recurrent events, the estimated risk could
be biased [21]. Hence, the commonly used Cox proportional hazard model will not be
appropriate here, due to the fact that correlation of the repeated occurrences is not
considered. As the recurrent event process tend to be related to longitudinal markers,
analyzing the two processes separately may lead to biased estimation. Thus, to propose
an statistical approach that jointly models longitudinal markers and recurrent events
together is of importance here.
First proposed by Faucett & Thomas [26] and Wulfsohn & Tsiatis [27], joint models (JM) of longitudinal measurements and survival data (including terminal event and
recurrent event data) have been widely studied in the past decades and a increasing
number of studies applied joint models to large clinical studies, e.g., Henderson et al.
[28], Han et al. [29] and Crowther et al. [30]. A common joint model often involves two
sub-models, one is a mixed effects model for longitudinal outcomes while the other is a
Cox model for survival events. In such setting, shared random effects are usually utilized
to link the two sub-models together. Previous literature compared and investigated the
association structure for random effects [45]. Some extensions of the joint models have
been developed, e.g., relaxing some of the normality assumptions of random effects in
order to make a more general assumption [31].
Another novel usage of JM is to provide dynamic prediction of the risk of target event
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and the trajectories of biomarkers. Rizopoulos [33] has developed methodology to make
personalized predictions using the joint model framework. The prediction is dynamic in
that the prediction can always be dynamically updated given the additional information
of longitudinal trajectories and longer history of survival process. Although there are
some literatures of the dynamic prediction problem under joint model of longitudinal
and survival data framework [34, 35], to our best knowledge, providing personalized
dynamic prediction in recurrent events in large CVD studies remains an open question.
Numerous prediction models estimating the risk of developing CVD events are either
simple survival model or logistic regression models [46]. To propose a prediction model
that incorporates clinical information and the recurrent disease history is of importance
here. In this article, we develop a Bayesian joint model approach to fit this critical need.
The proposed model consists of two sub-models, one is the linear mixed effect model to
model longitudinal trajectory, another is recurrent event model with intensity function
from Poisson process to handle the recurrent event process. The two sub-models are
linked via shared latent trajectory, while a parameter is assigned to access the strength
of association between these two process.
The rest of the article is organized as follows. In Section 2, we introduce the motivating cardiovascular disease study that motivates this article. The recurrent nature of the
CVD events is visually displayed. The joint model framework and dynamic prediction
method are illustrated in Section 3, upon which we propose our approach to model recurrent event process with longitudinal trajectory. We conduct simulations in Section 4
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to validate inference accuracy of our proposed model, the prediction performance is also
accessed by utilizing time-dependent Area Under the Curve (AUC) and Brier score (BS)
as indexes of prediction accuracy. In Section 5, we apply our proposed model on the
motivating dataset, the Parallel MCMC method is employed to address our computation
issue caused by large sample size. For prediction purpose, we also specify a traditional recurrent event model (referred as simple recurrent event model later), which only take into
account baseline covariates. The prediction performance of our model outperform simple
recurrent event model in regards of higher time-dependent AUC, indicating incorporation
of longitudinal clinical information improves subject-specific prediction accuracy for risk
of new CVD events. In the last section, we summarize the findings in our study, and
discuss limitation of our work and some possible future directions.

2.2

Motivating dataset

The methodological research is motivated by Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), a randomized, double-blinded, activecontrolled clinical trial conducted from February 1994 through March 2002 [3]. As the
primary outcome was composite fatal coronary heart disease (CHD) or non-fatal myocardial infarction (MI), the aim of ALLHAT study is to determine whether newer antihypertensive agents, including α-blocker doxazosin, differ from the reference treatment
chlorthalidone in regards of coronary heart disease events and other CVD events. During
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the study follow-up period, 15,255 subjects were randomized to chlorthalidone arm and
9,061 subjects were randomized to doxazosin arm, out analysis is conducted on subjects
from these two arms. The maximum follow-up time in analytical dataset was 5.57 years.
As death is treated as independent censoring in our study, subjects who were alive at the
end of the trial, or lost to follow-up during the trial are considered as independent termination (right censored). We are interested in the composite outcome of three types of
CVD recurrent events (CHD, stroke, heart failure) before death or censoring. To visualize
the data structure, we present Figure 2.1 to show the time plot of four selected subjects
who experienced composite CVD events before the end of their follow-up. For instance,
subject 1 experienced one CVD event in 59 month and was censored on 92 month, while
subject 4 experienced 5 recurrent CVD events and died in 67 month. Death process is
treated as non-informative censoring as our main interest lies in predicting next recurrent
event.
During the study, participants’ clinical information was collected and recorded during each scheduled visits. Systolic blood pressure (SBP) is the most frequently measured
clinical outcome in ALLHAT study. Utilizing this rich clinical information in predicting
the probability of having next recurrent event is of our interest. It is well established that
high blood pressure, i.e. hypertension is one of the main risk factors for CVD events, previous literature has studied the mechanisms of how high blood pressure can cause CHD,
stroke, heart failure [47]. In terms of prediction of risk of CVD events, hypertension,
as a known significant risk factor, is usually included in the statistical model. Staessen
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Figure 2.1: Data display of CVD events in ALLHAT study
et al [48] found that in untreated patients with isolated systolic hypertension, the systolic blood pressure predicted cardiovascular risk. More recent publications pointed out
there was significant positive relationship between higher SBP and CVD events [34, 46].
On the other hand, subjects with previous CVD have high risks of CVD recurrence
[49]. Thus, incorporating the SBP trajectory and recurrent disease history is essential
to personalized-prediction of next occurrence of a CVD event. Of the existing literature
about joint modeling of longitudinal measurements and recurrent events, Henderson [28]
proposed a joint model of longitudinal data and recurrent event data, with association
between two process captured by correlated latent trajectory. Moreover, Liu and Huang
[32] considered a more complex setting where a repeated measures process and a re18

current events process were correlated, both subject to a terminal event. While these
literature mainly focused on model inference, Krol et al [36] extended the usage of joint
model of longitudinal data, recurrent events, and a terminal event to dynamic prediction
area. They derived the estimated probability of having a terminal event in specific time
interval, given all previous history and no event occurred before prediction starting time.
Regarding prediction of recurrent events, Musoro et al [37] extended dynamic prediction
by landmarking to recurrent event data. Using landmark method, they handled the longitudinal data as time-fixed covariate at different landmark time point. However, to our
best knowledge, no research has been done in providing personalized dynamic prediction
in the recurrent events using joint model approach. In this article, we propose a joint
model of longitudinal data and recurrent event data and extend to dynamic prediction
of next occurrence of recurrent event within given time interval. Instead of using landmark method, the proposed joint model approach simultaneously models time updated
longitudinal biomarker and recurrent event process.

2.3
2.3.1

Methods
Joint model specification

Some clinical outcomes may occur in a recurrent fashion, making it important to investigate recurrent event data. In many studies, clinical bio-markers of targeted patients are
often collected longitudinally, utilizing this information helps us to identify risk factors
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of recurrent events and predict the risk of future occurrence. There are different ways
to incorporate longitudinal information in recurrent event model building, to model the
longitudinal process and recurrent event process at same time, we extend the typical
joint model method to handle recurrent event data.
Let y i (t) = {yi (tij )} be the vector of longitudinal observation for subject i at time tij ,
where i = 1, . . . , N , and j = 1, . . . , mi . Let Tik be the recurrent event times from study
onset for subject i, k = 0, . . . , ni , where ni denotes the number of recurrent cardiovascular
events (including CHD, stroke, and HF). We use a linear mixed effects sub-model to model
the longitudinal health outcome and a poisson intensity recurrent event sub-model for
modeling the re-occurrence of CVD events. These two sub-models are correlated by
random effects and expected values of longitudinal outcomes.
The joint model for recurrent event and longitudinal processes is:

yi (t) = X Yi (t)α + Z(t)i ui + V R (t)ζ + ei (t) = fi (t) + ei (t)
ri (t) =

r0 (t) exp{Z R
i β

(2.1)

+ νfi (t) + vi },

To allow flexibility and variation of baseline risk intensity, random effect vi is added in the
recurrent event submodel to explain the variation between subjects in baseline hazard.
We assume independence between ui and vi . The two sub-models are linked via an
association parameter ν, which quantifies the strength of correlation between the expected
longitudinal outcome and the hazard of recurrent CVD events. Parameters α and β
denote the estimated coefficients of longitudinal process related covariates and recurrent
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event process related covariates, respectively. One key assumption in the linear mixed
effects model is that all measurements from each patients are independent conditioning
on the random effects vector ui,1 and ui,2 . Thus, the likelihood for the longitudinal process
of subject i is:

liY

mi
Y



1
(yi (tij ) − X Yi (tij )α − Z i (tij )ui − V R (t)ζ)2
√
.
=
exp −
2σe2
2πσe
j=1

(2.2)

Under the assumption that the number of recurrent events in non-overlapping time intervals is a poisson process, we are able to model the event process via intensity function.
As in Eq (2.1), the covariate vector Z R
i can be identical or different from covariate vector X Yi in the longitudinal sub-model. To increase the robustness of our model fitting,
we utilize piece-wise constant baseline hazard model to obtain estimators for both fixed
effects and random effects. We divide the total follow-up time interval [0, τ ] by using
time knots τt = (0, τ1 , ..., τR ) by quantile of event times, and denote the baseline hazard
vector as g = (g0 , g1 , ..., gR−1 ). Then we can define the piecewise constant hazard function as h0 (t) =

PR−1
r=0

gr Ir (t), where indicator function Ir (t) = 1, if τr ≤ t < τr+1 and 0 if

otherwise. Therefore, the likelihood of the recurrent events process for subject i is:

liR

=
=

ni
Y

hi (tik )σik Si (xi )

k=0
ni 
Y



r0 (tik ) exp vi +

ZR
i β

δik
+ νfi (tik )



Z

· exp −
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r0 (t) exp vi +
0

k=0

xi

ZR
i β


+ νfi (t) dt ,

where δik is the indicator of a recurrent event at time tik and xi is the observed followup time. Here, the longitudinal outcome y i is assumed to be independent of time t,
conditioning on the random effects ui and v i . Thus, the full likelihood for subject i is

li = liY · liR · f (ui ) · f (v i ),

(2.3)

where f (ui ) and f (v i ) is the density function of ui and v i respectively. Our unknown
parameter vector is θ = {α, β, ν, σ1 , σ2 , ρ, σv , σζ , σe }.

2.3.2

Dynamic prediction

We randomly partition the dataset into two part, one is the training datasest which
is used to build the model, another is the validation dataset to access the prediction
performance of proposed model. After obtaining the posterior samples of parameter
vectors from inference of training dataset, we illustrate the derivation and procedure to
conduct dynamic prediction of each subject in validation dataset. Suppose a new subject
i had ni (e.g., ni = 0, 1, 2, · · · ) recurrent events up to time t, with longitudinal profile

y i (t) = {yi (tij ); 0 ≤ tij ≤ t}, we would like to predict his/her probability of having
the ni + 1 recurrent event before time t0 = t + ∆t (e.g., 1 year), denoted by πi (t0 |t) =
P (Ti,ni +1 ≤ t0 |Ti,ni +1 > t, y i (t), θ), where θ is the parameter vector in model (2.1).
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We can derive πi (t0 |t) as follows:

πi (t0 |t)
Z Z
=
P (Ti,ni +1 ≤ t0 |Ti,ni +1 > t, ui , vi , y i (t), θ)P (ui |Ti,ni +1 > t, y i (t), θ, vi )dui P (vi |Ti,ni +1 > t, θ)dvi

 Z t0
M
1 X
(m)
(m) (m)
(m)
ri (s|ui , vi , θ )ds .
1 − exp −
≈
M m=1
t
(2.4)
Here θ (m) is the mth sample (m = 1, . . . , M , where M is the number of post burn-in
(m)

samples) of parameter vector θ. For random effects, ui
(m)

ui and v i respectively. The term ri

(m)

and v i

is the mth sample of

denotes the intensity function from poission process

conditioning on mth copy of θ and corresponding random effects ui and v i . Detailed
derivation can be found in Appendix.
0

The key steps to approximate the event probability πi (t |t) are obtaining samples for
random effect ui and v i . The posterior samples of ui come from the posterior distribution
P (ui |Ti,ni +1 > t, y i (t), θ, vi ). Specifically, conditional on the mth posterior sample θ (m) ,
we draw the mth sample of ui from its posterior distribution

P (ui |Ti,ni +1 > t, y i (t), θ (m) , vi ) =

P (y i (t), Ti,ni +1 > t, ui |θ (m) , vi )
P (y i (t), Ti,ni +1 > t|θ

(m)

, vi )

∝ P (y i (t), Ti,ni +1 > t, ui |θ (m) , vi )

= P (y i (t)|ui , θ (m) )P (Ti,ni +1 > t|ui , θ (m) , vi )P (ui |θ (m) ),

where P (Ti,ni +1 > t|ui , θ

(m)

, vi ) =

Qni

k=0



r0 (tik ) exp{Z R
i β
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σik

+ νfi (tik ) + vi }
· exp −

Rt
0

r0 (s) exp



ZR
i β


+ νfi (s) + vi ds .

We then draw the posterior samples of vi from distribution P (vi |Ti,ni +1 > t, θ) as
follows:

(m)

P (vi |Ti,ni +1 > t, θ

(m)

(m)
, ui )

=
=

P (Ti,ni +1 > t, vi |θ (m) , ui )

∝ P (Ti,ni +1
(m)
P (Ti,ni +1 > t|θ , ui )
(m)
P (Ti,ni +1 > t|vi , θ (m) , ui )P (vi |θ (m) ),
(m)

(m)

> t, vi |θ (m) , ui )

For each of θ (m) , m = 1, . . . , M , we use adaptive rejection metropolis sampling
(ARMS) [50] in R HI package to draw 50 samples of ui and v i and retain the final sample.
This process is repeated for the M saved values of θ. Once the posterior distributions of
random effects are simulated, all calculations become straightforward and produce the entire distribution of the future trajectory (health outcomes and risk) of a new subject. For
(m)

example, the outcome trajectory at time t0 is yi (t0 )|ui ∼ N (Z i (t0 )Y α(m) + ui , σe2

(m)

).

Suppose that patient i does not have a recurrent event by time t0 , then the outcome
history is updated to y i (t0 ). We can dynamically update the posterior distribution to
p(ui |Ti > t0 , y i (t0 ), θ (m) ) and p(vi |Ti > t0 , θ (m) ), draw new samples of ui and vi , and
obtain the updated predictions.
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2.3.3

Bayesian inference

We use Bayesian inference based on Markov chain Monte Carlo (MCMC) posterior simulations to infer unknown parameters. We use non-informative priors on all parameters
in vector θ. To be more specific, the prior distribution of all elements in the coefficient
vectors α, β, and the the association parameter ν are normal distribution with mean
equal to 0 and standard deviation being 10. To ensure the positivity of variance parameter, we use inverse gamma distribution with α = 0.01, β = 0.01 as the prior distribution
of σ1 , σ2 , σv , σζ , σe , so the corresponding variance is 100. For the correlation parameter
ρ between random intercept and random slope, we use the uniform prior distribution
ρ ∼ U (−1, 1).
There are variety of MCMC sampler that can be used to conduct Bayesian inference,
including WinBUGS, OpenBUGS, JAGS, Stan and etc. We employ Stan to fit our proposed
model, because unlike WinBUGS, which uses Gibbs sampler, Stan uses Hamiltonian Monte
Carlo (HMC) sampler. Relying on deterministic mechanism inspired by Hamiltonian
dynamics, HMC method generates coherent exploration of target distribution. When
compared to standard Gibbs method, such approach not only improves posterior samples
convergence speed, but also gives the resulting estimator with stronger validity [51]. Our
proposed model is fitted in RStan while specifying aforementioned full likelihood function
and prior distributions of unknown parameters. To diagnose the convergence of posterior
samples, we use trace plot to decide the samples are converged if no apparent trends can
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be viewed from the plot. Another criteria to ensure convergence is Gelman and Rubin [52]
potential scale reduction statistic. we ensure the scale reduction statistics R̂ are smaller
than 1.1 for all parameters as an additional way to ensure convergence. In simulation,
2,000 after burn-in samples are draw for each parameter in θ, the convergence of these
posterior samples are ensured by meeting aforementioned criteria.

2.3.4

Parallelizing MCMC with Random Partition Trees

As large clinical studies being more and more prevalent, the scale of clinical datasets
has brought challenges to conventional MCMC sampling techniques. For these large
datasets, conducting Bayesian inference can be extremely time consuming. Moreover,
processing such large datasets in a single computer likely encounters the problem of nonsufficient memory. Although there are various attempts to address these issues [53, 54],
they either rely on asymptotic normality of posterior distributions, or have the drawback
of insufficient of resampling. To the end, Wang et al. [55] proposed a embarrassingly
parallel MCMC (EP-MCMC) approach to address the large sample size problem without
assuming any distribution of posterior samples. The theoretical property of this EPMCMC approach grants its good performance when being applied to different models.
The algorithm consists of two step, first it partitions the data into multiple subsets and
independently run MCMC sampler on each of them, then it applies random partition
trees to combine the posterior draws from subset.
Simulation is conducted to ensure EP-MCMC method is valid under our proposed
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model setting. The simulation setting is illustrated in Section 2.4. To conduct EPMCMC, we randomly divide 2000 samples into 10 subsets, each subset contains 200
samples and sufficient recurrent events. We then conduct Bayesian data analysis employing our proposed model in each subset, which results in 2,000 after burn-in MCMC
posterior samples for every parameter of interest. For example, for the 12 parameters, we
will have 10 matrices of size 2, 000 by 12, each coming from one subset. After obtaining
the posterior samples of parameters in multiple subsets, we implement PART algorithm
[55] in Matlab to combine the posterior samples from 10 subsets. This algorithm aggregates sub-chain posterior MCMC samples and draws a certain number of (e.g. 10,000)
samples for each parameter from the combined posterior with k-dimensional tree (k-d
tree) partition rules. Following aforementioned example, after we conduct the aggregation step, a matrix of size 10, 000 × 12 is obtained as the posterior samples for the
whole dataset. The posterior mean of the samples suggest that the parameters estimated
by this EP-MCMC approach have minor bias from the true values. Also, the coverage
probability does not show evidence of biased estimation or overly conservative standard
error estimates, which ensures the validity of this parallel MCMC approach under our
proposed model.
Besides the ability of dealing with large sample problem in application, EP-MCMC
method has additional benefit in regards of efficiency in estimating survival probabilities
of all subjects. To avoid over-fitting, we separate the whole data into 10 subsets and
estimate parameters in training set (consists of 9 of the subsets), dynamic prediction is

27

then conducted to estimate event-free probability in validation set (the unused 1 subset).
Instead of having to repeat the inference MCMC sampling process 10 times to get the
estimated survival probabilities for all subjects (each time, survival probabilities of subjects from 1 validation set are estimated), EP-MCMC method enables us to aggregate
posterior samples from selected 9 subsets to obtain the estimation of parameters in the
training set. In this way, we no longer need to run MCMC sampler for 10 times in each
pooled training set, but just use the posterior samples of different subsets to obtain inference results. As the Bayesian MCMC sampling technique is usually time-consuming,
this approach save a lot of computation time.

2.3.5

Assessing predictive performance

Accurate identification of patients with higher risk of having a new future event is one of
the most interested features in statistical models. It is important to access how well our
proposed risk prediction model performs and how accurately it predicts a future event
within specific given time period. Here, we access the prediction performance in three
aspect, global discrimination ability (the ability that the model correctly classifies event
and non-event.), validation performance (how well the model predicts the data), comparison with other model. To be more specific, we employ receiver operating characteristic
(ROC) curve and the area under the ROC curves (AUC) to assess the discrimination
ability of the proposed model, the validation performance is assessed using the expected
Brier score (BS). Moreover, we adopt the methodology approach proposed by Blanche
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et al. [34] to quantify and compare the predictive accuracy of different models.

Area under the ROC curves
Following the definition in previous section, for a given cut value c ∈ [0, 1], the time dependent sensitivity and specificity are P {πi (t0 |t) > c|D(t, t0 ) = 1, Ti∗ > t} and P {πi (t0 |t) ≤
c|D(t, t0 ) = 0, Ti∗ > t} respectively, where D(t, t0 ) is an indicator function equals to 1 when
a new event happen during time interval (t,t’] and equals to 0 otherwise. Therefore, for
0

0

0

0

probability p ∈ [0, 1], the ROC curves will be ROCtt (p) = T Ptt [F Ptt ]−1 (p), where T Ptt
0

denotes the true positive rate, F Ptt denotes the false positive rate [56]. With the defined time-dependent sensitivity and specificity, we calculate a standard “concordance”
summary: the time-dependent Area Under Curve (AUC), the formula is as following [57]:

0

Z

1

AU C(t, t ) =

0

ROCtt (p)dp.

0

With standard numerical integration methods, we can estimate the time-dependent AUC
straightforwardly, and it serves as a criteria to assess the global discrimination ability of
the proposed model.

Dynamic Brier score
By extending the Brier score (BS) defined in survival models to joint model framework [58], we are able to define the expected BS for dynamic prediction as BS(t, t0 ) =
E[(D(t0 |t) − π(t0 |t))2 ], here D(t0 |t) denotes the observed event status, which equals to 1 if
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subjects experience a new event during (t, t] and equals to 0 otherwise. As the dynamic
expected Brier score is a mean squared error, we can express it as

BS(t, t0 ) = E[(E[D(t0 |t)] − π(t0 |t))2 ] + E[(D(t0 |t) − E[D(t0 |t)])2 ].

The first term in aforementioned equation measures how close the predictions are to
expected event status E[D(t0 |t)], in other word, evaluates how well the models predict
the observed data. The second term is an aggregation of resolution and uncertainty and
does not depend on the distribution of the predictions. Both AUC and BS are interesting
statistics when assessing the predictive accuracy, and they complement each other when
quantifying the overall performance of the dynamic prediction probability π(t0 |t).

Comparing Dynamic Predictive Accuracy
While AUC and BS are well studied in quantifying the overall prediction performance of
a specific model, comparing these two indexes between different models is getting more
interest. By comparing the AUC and BS, it enables researchers to select appropriate
model which is useful enough regarding prediction purposes. Blanche et al. [34] proposed
a methodology approach to compute confidence regions of AUC and BS, also tests for
the difference of them in different models. The detailed derivations can be found in the
publication. As a consequence of the derivations, denoting either AUC(t, t0 ) or BS(t, t0 ) as
θ(t, t0 ), let θ̂(t, t0 ) denote the corresponding estimator and ∆θ̂(t, t0 ) denote the estimator
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of the difference of AUC or BS between two prognostic models at given landmark time
t. We are able to obtain the pointwise confidence interval

σ̂∆,t,t0
∆θ̂(t, t0 ) ± z1−α/2 √ ,
n

2
here z1−α/2 is the critical value of standard normal distribution and σ̂∆,t,t
0 is the empirical

estimator of variance, which can be consistently estimated by the influence function
following formulas in Blanche et al. [34]. Therefore, testing for comparison of two
prediction accuracy measurements can also be derived accordingly.

2.4

Simulation Setting

In this section, we examine the performance of parameter inference and prediction of the
proposed model via simulation. Consider binary covariates for xi1 , xi2 which equals to
0 or 1 with probability 0.5. We generate the longitudinal measure Yi (tij ) at time tij of
subject i as yi (tij ) = α0 + α1 xi1 + α2 xi2 + α3 tij + ui1 + ui2 tij + ei (tij ), where the error term
i follows normal distribution, i.e. ei (tij ) ∼ N (0, σe2 ), i = 1, . . . , I, and j = 1, . . . , mi . For
recurrent event process, we assume non-informative censoring, the censoring time Ci is
sampled from uniform distribution U nif orm(9, 10) with 50% censoring rate. Let Tik be
the kth recurrent event times from study onset (time 0) for subject i, k = 0, . . . , ni , where
ni denotes the number of recurrent events. Let ri (t) denote the intensity of the recurrent
process. Random intercept ui1 and random slope ui2 follows multivariate normal distri31

bution with mean 0. And the covariance matrix is denoted by Σu , with σ12 , σ22 denote the
variance for random effects ui1 , ui2 respectively while ρ represents the correlation between
two random variables. On the other hand, vi is the random variable only associated with
recurrent process and independent of ui1 and ui2 , we assume that it follows a normal
distribution with variance denoted by σv2 . Our simulation setting is as follows:

yi (tij ) = α0 + α1 xi1 + α2 xi2 + α3 tij + ui1 + ui2 tij + ei (tij ) = fi (tij ) + ei (tij )
ri (tik ) = r0 exp{β1 zi + νfi (tij ) + vi }

The inference results is based on 200 simulations with training sample size equal
to 600, on average, there are 2 recurrent events per subject. Table 2.1 displays the
bias of estimated parameter with true value, standard deviation of posterior mean (SD),
standard error (SE), coverage probability (CP), and root mean squared error (RMSE)
of inference results. The simulation results without using Parallel EP-MCMC method is
summarized in left panel of Table 2.1. To evaluate the performance of Parallel EP-MCMC
method under our proposed model setting, we randomly divide the training dataset into 3
subsets and apply the EP-MCMC method following aforementioned procedures in Section
2.3.4. We present the results in Table 2.1 right panel. The results suggest that under
simulation settings, parameters estimated by our proposed model have minor bias with
true value, small RMSE, and the coverage probability (close to 0.95) does not show
evidence of biased estimation or overly conservative standard error estimates. After
the inference is done, we apply our proposed dynamic prediction method in validation
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Parameter
α0 =−1.000
α1 =−0.200
α2 =0.800
σ1 =1.500
σ2 =0.150
σv =0.200
ρ=0.400
σe =5.000
β1 =−0.12
ν=0.750

Results without Parallel MCMC
Results with Parallel MCMC
BIAS
SD
SE
CP RMSE
BIAS
SD
SE
CP RMSE
0.001 0.169 0.184 0.960
0.169
0.010 0.175 0.184 0.955
0.175
−0.007 0.235 0.244 0.955
0.235 −0.011 0.241 0.244 0.960
0.240
0.000 0.037 0.038 0.955
0.037
0.000 0.037 0.038 0.955
0.037
−0.005 0.123 0.138 0.970
0.123 −0.003 0.123 0.138 0.970
0.123
0.008 0.025 0.030 0.980
0.026
0.007 0.025 0.030 0.985
0.026
0.001 0.039 0.041 0.960
0.039
0.001 0.040 0.041 0.955
0.040
0.006 0.183 0.244 0.995
0.183
0.008 0.184 0.245 0.995
0.183
−0.001 0.068 0.065 0.940
0.067
0.000 0.065 0.065 0.950
0.065
0.003 0.025 0.025 0.955
0.025
0.002 0.025 0.025 0.960
0.025
−0.001 0.039 0.042 0.980
0.039 −0.001 0.038 0.042 0.980
0.038
Table 2.1: Parameter estimates in simulation

dataset, which contains 200 new subjects who has never been used in training. Results
for dynamic prediction in validation dataset are presented in Table 2.2. Here AUC is
the average of all AUC calculated within given time interval for 200 simulation times.
The last column represents the average bias of the estimated event-free probability and
the true probability that calculated using true value of parameters. The estimated AUC
and BS are acceptable rate, and bias are all under 0.005. In conclusion, the simulation
results suggest that our proposed model gives close estimation of parameter vector, also
has a good prediction performance.
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t
5

6
7

t0
6
7
8
9
7
8
9
8
9

AUC
0.746
0.756
0.759
0.761
0.788
0.788
0.789
0.814
0.812

BS
0.014
0.016
0.017
0.020
0.016
0.017
0.019
0.018
0.021

Bias
0.002
0.003
0.004
0.004
0.003
0.004
0.005
0.003
0.004

Table 2.2: Time-dependent AUC in simulation

2.5

ALLHAT Study Application Results

In this section, we apply the proposed joint model to the motivating ALLHAT study.
Considering the recurrent non-fatal cardiovascular disease events (composite CHD, stroke,
and heart failure) as our primary survival outcome, we select SBP as our longitudinal
biomarker which showed significant association with time to CVD events in previous
literatures. The longitudinal process and recurrent event process are related by sharing
an underlying latent function, an association parameter serves as an measurement of the
relationship between longitudinal biomarker and recurrent CVD events.
A number of potential risk factors of cardiovascular disease are assessed and evaluated
in previous related studies, including age, gender, diabetes, hypertension, history of
cardiovascular disease, alcohol consumption, tobacco use, family history of cardiovascular
disease, environmental factors, etc. [44, 59]. We pre-select the following risk factors to
be included in our analysis upon availability of the ALLHAT data: trial randomization
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group (0 if chlorthalidone, 1 if doxazosin), age (in year), gender (0 if female, 1 if male),
race (0 if white and others, 1 if black), diabetes (0 if no, 1 if yes), history of MI or
Stroke at baseline (0 if no, 1 if yes), history of coronary revascularization (0 if no, 1
if yes), antihypertensive treatment before trial (0 if no, 1 if yes). These covariates are
separately tested to be significant either the linear mixed effect model or the recurrent
event model. After excluding subjects with pending death confirmation pending and
those with missing data in aforementioned covariates, we obtain the analytical dataset
with total 19,804 subjects. Among these subjects, 16,811 subjects are cardiovascular
disease events free until the end of follow-up period, 2,179 subjects experienced 1 event,
and 814 subjects experienced more than 1 events during the follow-up of the study.
Due to the fact that ALLHAT study is one of the largest cardiovascular disease studies
in U.S. and our analysis include around 20,000 subjects, running MCMC sampler to get
posterior samples of model parameters in the whole dataset can be very time consuming.
In order to speed up the computation, we adopt the parallel MCMC approach in Section
2.3.4. To employ EP-MCMC method, we divide the analytical dataset into 10 partitions,
each partition includes around 2,000 randomly sampled subjects. In each of the 10
subsets, we run two parallel MCMC chains with overdispersed initial values and each
chain is ran for 5,000 iterations. The first 3,000 iterations are discarded as burn-in and the
inference of all parameters are based on remaining 2,000 iterations from each chain. We
employ piece-wise constant baseline hazard function in our analysis. To ensure we have
enough observations in each piece-wise interval, we construct intervals by every 1/4th
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quantile of the CVD events time in ALLHAT dataset. Good mixing and convergence
properties of the MCMC chains are ensured in trace plots and R̂ for each parameter is
below 1.01.
Parameters estimation using aforementioned method are presented in Table 2.3. For
longitudinal sub-model, the results suggests that there is significant different in randomization drug group, on average, the systolic blood pressure for subjects in doxazosin
group is 2.796 units (95% CI [2.428, 3.143]) higher than chlorthalidone group. Other risk
factors including age, gender, race, and baseline anti-hypertensive drug usage are found
to have significant effects on the systolic blood pressure. Specifically, 1 year increase
in age increases the systolic blood pressure by 0.136 units (95% CI [0.111, 0.162]) on
average. When compared to female subjects, male tend to have 1.2 units (95% CI [0.808,
1.584]) lower systolic blood pressure. On average, black subjects have 2.388 units (95%
CI [2.008, 2.773]) higher systolic blood pressure when compared to others. Subjects who
took anti-hypertensive drugs before baseline have 1.119 units (95% CI [0.469, 1.760])
higher systolic blood pressure than others. The results are consistent with the primary
ALLHAT publications [60]. For recurrent event sub-model, we find that subjects with diabetes history have significantly higher risk to develop new cardiovascular disease events
(RR= 1.578; 95% CI [1.418, 1.742]). Similar effects can be found in subjects with MI or
stroke (RR= 1.941; 95% CI [1.740, 2.160]), and subjects with history of coronary revascularization (RR= 2.175; 95% CI [1.923, 2.479]). Moreover, the association parameter ν is
statistically significant, indicating the longitudinal systolic blood pressure measurements
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Mean

2.5%

97.5%

SD

longitudinal submodel
Intercept
Trt(doxazosin)
Age(years)
Male
Black
BL Antihypertensive drug (Yes)
σ1
σ2
ρ
σe

2.688
1.962
3.412 0.393
2.796
2.428
3.143 0.186
0.136
0.111
0.162 0.013
1.200
0.808
1.584 0.209
2.388
2.008
2.773 0.196
1.119
0.469
1.760 0.339
12.159 11.947 12.364 0.107
3.333
3.222
3.441 0.056
−0.563 −0.584 −0.541 0.011
12.416 12.363 12.470 0.028

recurrent event submodel
Diabetes (Yes)
History of MI or Stroke
History of coronary revascularization
Association

0.456
0.663
0.777
0.016

0.349
0.554
0.654
0.011

0.555 0.054
0.770 0.054
0.908 0.065
0.020 0.002

Table 2.3: Parameters estimation results
are positively associated with the risk of recurrent CVD event with a rate at 0.006 (95%
CI [0.001, 0.010]).
To assess and compare the prediction performance, we calculate time-dependent AUC
and BS of our proposed model (Model 1) and a simple recurrent event model (Model 2).
We present the estimated AUC and BS of different prediction time windows in Table 2.4.
The result suggests that our proposed model have higher AUC and lower BS than simple
recurrent event model in every prediction interval, suggesting that using longitudinal
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biomarker improves the prediction of patient’s risk of developing a new recurrent event.
The results also indicate that using more longitudinal and disease information tend to
improves the model prediction performance. For later prediction starting time, updated
SBP measurements are used in predicting risk of having a recurrent event, therefore the
prediction performance is improved.
To compare the dynamic prediction accuracy curves of these two prognostic models,
we employ the testing method proposed by Blanche et al. [34]. To illustrate the comparison results, we plot the estimated AUC of Models 1 and 2 (upper panels) as well as the
difference of mean AUC from these two prognostic models (lower panels) in Figure 2.2.
The first graph of upper and lower panels displays the estimated AUC and difference of
AUC respectively for prediction landmark time year 1 with four prediction time windows
considered (0.25 year, 0.5 year, 0.75 year, and 1 year). Other graphs are constructed in a
similar fashion, but with different prediction landmark time (year 2, year 3, and year 4).
We find that for all landmark times, AUC from our proposed model (Model 1; solid black
line) is higher than it from simple recurrent event model (Model 2; solid gray line), and
the corresponding difference of AUC is above 0 for every prediction time window. For
prediction after year 1 visit, the estimated difference of AUC from Model 1 and 2 for 0.5,
0.75, and 1 year prediction window are significant at 0.05 level. Similarly, for prediction
made after year 2 visit, there is a significant difference of estimated AUC between Model
1 and 2 for 0.75 and 1 year prediction window at 0.05 significance level. On the other
hand, the differences of AUC estimated from predictions made after year 3 and year 4
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t(year)
1

2

3

4

∆t(month)
3
6
9
12
3
6
9
12
3
6
9
12
3
6
9
12

Model 1
AUC
BS
0.665 0.015
0.676 0.027
0.675 0.038
0.668 0.049
0.660 0.015
0.653 0.028
0.658 0.041
0.651 0.041
0.706 0.017
0.695 0.034
0.676 0.049
0.658 0.065
0.744 0.020
0.696 0.067
0.685 0.059
0.643 0.077

Model 2
AUC
BS
0.556 0.015
0.556 0.028
0.557 0.040
0.558 0.051
0.572 0.015
0.566 0.029
0.559 0.052
0.553 0.052
0.652 0.017
0.603 0.035
0.604 0.052
0.598 0.070
0.639 0.021
0.616 0.069
0.576 0.063
0.576 0.080

Table 2.4: Time-dependent AUC and BS for proposed joint model (Model 1) and reference
recurrent event model (Model 2)
from these two models are not significant at 0.05 level.
We select two subjects who experienced different occurrences of cardiovascular disease
events to illustrate our subject-level prediction results. Conditioning on their available
measurements, we predict their future longitudinal trajectory as well as the probability
of developing a new event in given time interval. With 11 recorded longitudinal SBP
measurements, subject 127 (upper panels) experienced total 5 recurrent CVD events
before year 4. Subject 15 (lower panels) had 13 recorded SBP measurements and only
had one CVD event during year 2 and year 3. Figure 2.3 presents the estimated SBP from
year 1 to year 5 for both subjects. When only 1 year information is used in prediction,
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Figure 2.2: Compare AUC for proposed joint model (Model 1) and reference recurrent
event model (Model 2)
the 95% confidence bands of both subjects are relatively wide, by using more follow-up
data, the 95% confidence band is narrower. Most of the actual SBP measurements fall
into the prediction confidence interval.
Besides the prediction of future trajectory of SBP, predicting the probability of having
a new CVD event in future is more of clinical interest. We illustrate the prediction
patterns of aforementioned two subjects in Figure 2.4. The upper penal of Figure 2.4
presents the event-free probability from different landmark time to year 5 for subject 127,
while the lower penal presents the probability for subject 15. Based on 1 year information,
subject 15 has a lower event risk between year 2 and year 5 when compared to subject
127 (the first plot of upper and lower panels). When year 2 data become available,
the prediction dynamically updates and the risk of having new CVD event decreases as
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Figure 2.3: Predicted SBP measurements for Subject 127 (upper panels) and Subject 15
(lower panels) in ALLHAT study. Dashed lines are the 2.5% and 97.5% percentiles. The
dotted vertical line represents the time of prediction t.
no event occurred for both of the subjects (the second plot of upper and lower panels).
However, for subject 127, predicted event risk after year 3 and year 4 increases sharply as
multiple CVD events occurred during this time interval (the third and last plots of upper
panels). Clinicians may closely monitor the subject and take personalized treatment
based on the prediction. A pattern which is similar to longitudinal trajectory prediction
is that when more data come into available, the prediction becomes more precise as the
confidence band narrows down.
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Figure 2.4: Predicted CVD event free probability for Subject 127 (upper panels) and
Subject 15 (lower panels) in ALLHAT study. Dashed lines are the 2.5% and 97.5%
percentiles.

2.6

Discussion

In this article, we propose a joint model of a longitudinal outcome and a recurrent event
process and apply our proposed model in ALLHAT dataset. The longitudinal process
and recurrent event process are correlated via shared latent function, an association parameter is set to model the relationship between these two process. The simulation study
indicates that the coefficients of covariates in both submodel and the association parameter estimated using our proposed model have small bias to true value and appropriate
coverage probability. Dividing the simulated dataset to training set and test set, we
conduct personalized prediction for each simulated sample in test set, and compute their
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probability of having an new event in given time interval. The prediction performance is
assessed by time-dependent Area Under Curve and dynamic Brier score. The Area Under
Curve and Brier score estimated using our proposed method are at acceptable rate and
mean survival probability bias are all below 0.005, indicating our proposed prediction
approach has good performance. We then apply our proposed model in ALLHAT study.
To address the computation issue caused by the large sample size of ALLHAT study, we
employ parallel MCMC method to do inference of parameters parallelly, which significantly reduce our computing time. In every given prediction time interval, our proposed
model outperforms the simple recurrent event model in regards to AUC, which indicates
that utilizing subject-specific longitudinal information helps improve prediction accuracy
of having a new event in near future.
There are some possible future directions that we would like to pursue. One limitation of our proposed model is that we treat death as non-informative censoring. This
assumption might not be true as death process can be related to longitudinal biomarker
or recurrent events. Joint model for the three correlated outcomes was proposed by recent
work in related area [32, 36]. Adding another submodel for death process, Liu & Huang
[32] proposed a joint random effects model with correlation between longitudinal process,
recurrent event process and death process modeled by shared random effects. Moreover,
Krol et al [36] not only proposed a trivariate joint model for longitudinal data, recurrent
events and a terminal event, but also extended the dynamic prediction for death process.
However, to our best knowledge, no work has been done regarding dynamic prediction
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for recurrent events. In the future work, we will extend the proposed model to take death
process into account while predicting future occurrence of recurrent events.
Another limitation of our work is that we only consider predicting future CVD events
utilizing under joint model framework, while the longitudinal trajectory is modeled via
linear mixed-effect submodel. Other methods including Principal Analysis by Conditional
Expectation (PACE) can be utilized to model longitudinal data without making linear
assumptions. In future studies, we plan to compare the prediction ability of these two
methods. As the occurrence of CVD events are usually related with multiple biomarkers
(e.g. serum cholesterol level, serum creatinine), including only longitudinal blood pressure
measurements in prediction model may results in relatively low AUC in our analysis.
Multivariate Functional Principal Component Analysis (MFPCA) method proposed by
Happ et al. [61] is a promising way to incorporate multiple longitudinal biomarkers in
predicting recurrence of CVD events. By leveraging other longitudinal outcomes, we may
be able to improve the prediction performance in future studies.
Moreover, numerous GWAS studies have been conducted in CVD area, incorporating genetic information in our prediction framework may improve prediction accuracy.
ALLHAT study also collected genetic information of participants during follow-up, how
to efficiently utilize these GWAS data to do the dynamic prediction warrants further
investigation.
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Appendix
We can derive πi (t0 |t) as follows:

πi (t0 |t)
Z Z
=
P (Ti,ni +1 ≤ t0 |Ti,ni +1 > t, ui , vi , y i (t), θ)P (ui |Ti,ni +1 > t, y i (t), θ, vi )dui P (vi |Ti,ni +1 > t, θ)dvi
Z Z

P (Ti,ni +1 ≤ t0 |Ti,ni +1 > t, ui , vi , θ)P (ui |Ti,ni +1 > t, y i (t), θ, vi )dui P (vi |Ti,ni +1 > t, θ)dvi

Z Z

P (t < Ti,ni +1 ≤ t0 |ui , vi , θ)
P (ui |Ti,ni +1 > t, y i (t), θ, vi )dui P (vi |Ti,ni +1 > t, θ)dvi
P (Ti,ni +1 > t|ui , vi , θ)

Z Z

P (Ti,ni +1 > t|ui , vi , θ) − P (Ti,ni +1 > t0 |ui , θ)
P (Ti,ni +1 > t|ui , vi , θ)

=
=
=

· P (ui |Ti,ni +1 > t, y i (t), θ, vi )dui P (vi |Ti,ni +1 > t, θ)dvi
Z Z
P (Ti,ni +1 > t0 |ui , vi , θ)
=1−
P (ui |Ti,ni +1 > t, y i (t), θ, vi )dui P (vi |Ti,ni +1 > t, θ)dvi
P (Ti,ni +1 > t|ui , vi , θ)
Z Z
S(t0 |ui , vi , θ)
=1−
P (ui |Ti,ni +1 > t, y i (t), θ, vi )dui P (vi |Ti,ni +1 > t, θ)dvi
S(t|ui , vi , θ)
 Z t0

Z Z
=1−
exp −
ri (s|ui , vi , θ)ds P (ui |Ti,ni +1 > t, y i (t), θ, vi )dui P (vi |Ti,ni +1 > t, θ)dvi
t

1
≈
M

M
X



Z

1 − exp −

m=1

t0

(m)
(m) (m)
ri (s|ui , vi , θ (m) )ds


.

t

Here θ (m) is the mth sample (m = 1, . . . , M , where M is the number of post burn-in
(m)

(m)

samples) of parameter vector θ and ui , v i
and v i respectively.
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is the mth sample of random effects ui

Chapter 3

Article 2: Predicting time to PD progression using
multiple longitudinal outcomes in PPMI study
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Predicting time to H&Y stage reaching 3 using
multiple longitudinal outcomes in PPMI study

3.1

Introduction

Parkinson’s disease (PD) is a progressive, chronic neurodegenerative disease that affects
patients’ movement. In the absence of a curative treatment, there is an critical need to
identify significant and well-validated biomarkers associated with PD progression [10].
Moreover, there is an increasing interest in utilizing these disease related markers to
build prognostic model of PD progression. Previous literature studied a broad range of
motor and non-motor symptoms which are clinically correlated with evolution of Parkinson’s disease [7–9]. However, due to substantial heterogeneity of different symptoms and
subjects, it is hard to give accurate prognoses of disease progression. A lot of effort has
been made to build prediction models of PD outcomes based on single or multiple related
markers.
As a complex progressive disease, a variety of endpoints have been established to evaluate PD severity and work as a criteria to categorize subjects into different disease stages.
Among these measures, Hoehn and Yahr (H&Y) scale has became one of the most commonly and widely used measurement to assess overall PD dysfunction stage [13]. Schrag
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et al. [14] examined the responsiveness of different PD progression outcome measures
over time and suggested the H&Y scale to be the most responsive measure. Based on
motor functions, the H&Y scale has served as a good endpoint of PD progression in many
published studies. The time to development of different H&Y stages from symptom onset
or enrollment has been widely studied as a way to evaluate disease progression in past
literature [15–18]. Although these literature discussed potential prognostic factors in predicting the H&Y stage progression, only baseline variables were included in the survival
model and longitudinal information was not taken into account. Relatively few studies considered modelling longitudinal marker in prediction of PD disease outcome. He
and Luo [19] proposed a joint model with multilevel item response theory sub-model for
the longitudinal data and Cox propotional hazard sub-model to handle time to terminal
event. They assessed the effect of tocopherol on time to initiation of symptomatic therapy
in early PD patients. Iddi et al. [20] applied a latent time joint mixed-effects model to
handle longitudinal outcomes and studied the association between different markers and
PD diagnostic category. However, to our best knowledge, no previous research has been
done regarding prognostication of time to the H&Y stage transition based on multiple
longitudinal markers.
Aiming at developing a prognostic model for time to disease progression measured by
H&Y stage transition, we incorporate longitudinal information from varies of clinical
markers by employing cutting-edge multivariate functional principal analysis (MFPCA)
method in this study. We apply the proposed model to data from the Parkinson’s Pro-
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gression Marker Initiative (PPMI) study, which collected a broad range of clinical markers that were frequently measured for untreated PD patients. External validation is
conducted in The Longitudinal and Biomarker Study in PD (LABS-PD) to assess the
prediction performance of the established prognostic model across different PD studies.
A set of prognostic index is estimated to calculate subject-level risk scores and can be
updated when new measurements come into available. The proposed approach enables
physicians to make clinical decision based on prognosis from enriched information, moreover, identifying PD patients with higher risk of disease progression according to expected
prognostic risk score helps clinicians give adaptive treatment to targeted patients.

3.2

Patients

The Parkinson’s Progression Marker Initiative is a multicenter study of patients across
North America, Europe, Israel, and Australia. Detailed information regarding study
design, inclusion and exclusion criteria, and study protocols can be fould at https:
//www.ppmi-info.org/. Aiming at identify one or more markers of progression for
Parkinson’s disease (PD), the PPMI study recruited 423 newly diagnosed PD cases, who
must be untreated for PD at the time of enrollment. Clinical measurements, imaging
data and biological samples are collected longitudinally over a period of 6 years. For PD
patients, subjects were scheduled to visit sites every 3 months from enrollment during
their first year, and follow-up visits were conducted every 6 months. The LABS-PD pro-
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gram, whose main goal is developing biomarkers that measure risk for PD progression,
enrolled total 537 PD subjects at baseline [62]. Multiple motor and non-motor markers
were evaluated annually during study follow up period. Before initiating the study, all
sites of PPMI study and LABS-PD have been approved by the institutional review board,
and all study participants from both studies were given a written informed consent for
research.
Our interest is to study the prediction ability of multiple longitudinal risk factors for
disease progression. Following definition in study conducted by Müller et al [15], we
define time to PD progression as time from enrollment to patients reach H&Y stage 3,
which will be our primary outcome. Among all PD subjects from PPMI study, 3 of them
already reached H&Y stage 3 at baseline and has been excluded in following analysis.
We select the candidate longitudinal risk factors that were suggested to have association with PD progression in previous literature [63] and are available in PPMI study:
Movement Disorder Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS),
Montreal Cognitive Assessment (MoCA), total Scale for Outcomes in Parkinson’s - autonomic questionnaire (SCOPA-AUT), Modified Schwab and England Activities of Daily
Living Scale (SEADL), Symbol Digit Modalities Test (SDM), Geriatric Depression Scale
(GDS), Letter Number Sequencing (LNS), Semantic verbal fluency and Questionnaire
for Impulsive-Compulsive Disorders in Parkinson’s Disease (QUIP). Cerebrospinal fluid
(CSF) biomarkers including total tau (t-tau), phosphorylated tau (p-tau) and amyloidbeta (Aβ1−42 ), which have been suggested as significant predictor for PD progression
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Total
Age (years)
Education (years)
Male
White
Right handed
Years of PD diagnosis (years)
MDS-UPDRS 1
MDS-UPDRS 2
MDS-UPDRS 3
MoCA
SDM
SEADL
QUIP
SCOPA-AUT
t-tau
p-tau
Aβ1−41

Progressed to Not progressed to
Combined
H&Y stage 3
H&Y stage 3
98
325
423
66.01 (9.40)
60.39 (9.44)
61.70 (9.72)
15.47 (2.74)
15.56 (3.07)
15.54 (2.99)
58 (59.18%)
219 (67.38%)
277 (65.48%)
93 (94.90%)
308 (94.77%)
401 (94.80%)
87 (88.78%)
288 (88.62%)
375 (88.65%)
0.62 (0.61)
0.53 (0.53)
0.55 (0.55)
7.67 (5.01)
4.93 (3.50)
5.57 (4.06)
7.86 (4.48)
5.30 (3.92)
5.89 (4.19)
24.09 (8.46)
19.93 (8.76)
20.89 (8.86)
26.81 (2.51)
27.24 (2.25)
27.14 (2.32)
37.34 (9.49)
42.34 (9.51)
41.18 (9.73)
91.84 (6.19)
93.54 (5.74)
93.14 (5.89)
0.35 (0.73)
0.34 (0.89)
0.34 (0.86)
10.63 (5.75)
7.75 (5.25)
8.42 (5.50)
49.29 (22.03)
43.36 (16.83)
44.69 (18.28)
15.33 (10.30)
15.73 (9.99)
15.64 (10.05)
347.36 (103.68)
377.33 (98.55) 370.56 (100.39)

Table 3.1: Descriptive statistics measured at baseline of PPMI participants.
[64–66], are considered as potential risk factors in our analysis. Baseline characteristics
including patients’ age, gender and years of PD diagnosis are controlled in the prediction
model. We present the sample size and descriptive statistics for key baseline variables in
Table 3.1.
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3.3

Statistical Analysis

To model the time-to-event outcome (e.g. PD progression defined as HY stage reach 3)
accounting for multiple available longitudinal biomarkers, we adopt a novel approach integrating features of longitudinal trajectories. By assuming there exists a latent process for
observed measurements of each longitudinal biomarker, we employ functional principal
component analysis (FPCA) approach to extract the features of each longitudinal process
[38]. While the mean trajectory of a longitudinal marker is estimated by entire sample
set, a set of subject-specific FPC scores for this biomarker is calculated to summarize the
changing pattern in individual level. There are two advantages when utilizing FPC scores
to capture longitudinal feature of subjects. First, by employing FPCA method, we do
not assume a trajectory model. In most cases, it is hard to specify a proper parametric
model for longitudinal process, and a miss-specified model will lead to biased estimation
and inaccurate prediction. Second benefit is that while extracting features of longitudinal measurements, we use the observed values only, which means we allow subjects to
have different missing visits from one to another, and no need to impute the missing
values while calculating FPC scores. Moreover, with the eigenfunctions and eigenvalues
obtained from FPC analysis, we are able to reconstruct the longitudinal process and
estimate the value of biomarker at given time point. This feature of FPCA enables us
to handle irregular missing visits among study subjects while provides a practical way to
estimate missing values. However, one potential drawback of using FPCA on multiple
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markers separately is that, it is likely for the markers to have significant correlations between each other, which could cause the FPC scores computed from candidate markers
become highly correlated and fail the independent covariates assumption in subsequent
analysis. To solve this problem, We adopt multivariate functional principal component
analysis (MFPCA) method proposed by Happ et al [61] to properly address this issue.
Unlike using separate FPCA which fail to assess the joint variation of markers, MFPCA
captures the joint variation of markers and addresses the potential correlation directly
while estimating the matrix of covariances. As consequence, the MFPC scores derived
from candidate markers are uncorrelated and more parsimonious when compared with
separate FPC scores. To model the survival outcome integrating the impact of multiple
longitudinal markers, we use the MFPC scores to represent the feature of trajectories
and put them in the Cox-PH model as new risk factors.

3.3.1

MFPCA

To illustrate Multivariate FPCA method, we first introduce the univariate FPCA approach. The principal component model was first proposed by James et al. [67]. Let
Xi (t) denote the underlying latent longitudinal process for subject i, i = 1, · · · , n. We denote the total follow up time of the study as τ . The observed survival time is denoted by
Ti , which is the minimum of subject’s survival time Si and censoring time Ci . Let Zi (t) =
Zi1 (t), · · · , Zir (t) denote vector of candidate covariates valued at time t that have signifi54

cant effects on longitudinal process, and Vi (t) = Vi1 (t), · · · , Vis (t) represent the covariates
valued at time t associated with recurrent event processes. Let µ(t) be the overall mean
effect of longitudinal process without considering covariates Zi (t), then the mean function
of longitudinal process is: µi (t) = µ(t|Zi ) = µ(t) + βZi (t), where β denotes the coefficients of covariates associated with longitudinal data. Define G(s, t) = cov(Xi (s), Xi (t)),
and denote orthogonal eigenfunctions as φk , k = 1, 2, · · · , non-decreasing eigenvalues as
λk , k = 1, 2, · · · , then we can write G(s, t) =

P

k

λk φk (s)φk (t). From Karhunen-Loéve

theory [68], individual trajectory Xi (t) can be expressed as Xi (t) = µi (t) +
here coefficients ξik =

Rτ
0

P

k ξik φk (t),

{Xi (t) − µi (t)}φk (t)dt are uncorrelated random variables with

2
mean zero and variances Eξik
= λk . By supposing that G can be approximated by first

finite terms in eigen-decomposition, we can truncate the eigenfunctions and model the
trajectory using first K leading principal components, Xi (t) = µi (t) +

PK

k=1 ξik µk (t).

Let

Yij be the observation of longitudinal process at time tij , we can express the longitudinal
observation Yij as:

Yij = Xi (tij ) + ij = µ(tij ) +

M
X

ξin φn (tij ) + ij .

n=1

where ij is measurement error with mean zero and variance σ 2 and is independent of
ξik . Note that we can model the eigenfunctions using expansions of a set of smooth basis
functions, such as B-splines or regression splines.
The principal analysis by conditional estimation (PACE) algorithm was proposed by
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Yao, Müller & Wang [38] to estimate the mean function µ(tij ), covariance function
G(s, t), eigenfunction φn and FPCA scores ξ n , where n = 1, · · · , M . The PACE method
was demonstrated to be powerful when applied to sparse longitudinal data with noise.
Basically, the estimated mean function µ̂(tij ) is obtained by a one-dimensional kernel
smoother, following the estimation of mean function, the covariance matrix Ĝ can be estimated by a two-dimensional kernel smoother with pairwise products {Yij − µ̂(tij )}{Yil −
µ̂(til )}. Thus we are able to obtain eigenfunctions φ̂n and eigenvalues λ̂n , n = 1, · · · , Mj ,
by spectral decomposition of covariance matrix Ĝ. Based on the estimation results,
the FPCA scores for longitudinal trajectory of subject i can be estimated by ξi,n =
R

(Zi (t) − µ(t))φn (t). Other than integration, Yao, Müller & Wang [38] proposed an-

other way to estimate FPCA scores by assuming ξi,n and ij are independent. Define
ΣYi = cov(Zi , Zi ) + σ 2 I, it can be estimated following details given in Yao, Müller &
Wang’s paper [38].Thus, we can estimate univariate FPCA scores based on its conditional expectation, specifically:

0
ξˆi,n = Ê(ξi,n |Yi ) = λ̂n φ̂n (tij )Σ̂−1
Yi (Yi (tij ) − µ̂(tij )).

MFPCA method proposed by Happ & Greven [69] provides a way to extract features
of multiple longitudinal outcomes while capturing the joint variation between different
outcomes. Let X(t) denote the vector that combined p different functions, i.e, X(t) =
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(X (1) (t), · · · , X (j) (t), · · · , X (p) (t)), where j = 1, · · · , p. Following the assumptions for
univariate FPCA, multivariate Karhunen-Loéve theory give a representation as:

X(t) = (X (1) (t), · · · , X (j) (t), · · · , X (p) (t))
=

∞
X

(1)
ρ m ψm
(t), · · · ,

m=1

∞
X
m=1

(j)
(t), · · · ,
ρ m ψm

∞
X

!
(p)
(t)
ρm ψm

m=1

here multivariate FPC score ρ = (ρ1 , ρ2 , · · · , ρm , · · · ) are random variables with zero
mean, ψm is an orthonormal basis of Hilbert space. The eigenvalue νm represents the
amount of variability in X that explained by corresponding multivariate functional principal components ψm , while the multivariate FPC scores ρm serves as weights of ψm . As
non-decreasing eigenvalues νm goes to 0 when m → ∞, we can truncate the KarhunenLoéve expression using first M components of ψm , M can be selected using model selection techniques (e.g. AIC, backward selection, proportion of variance explained, etc.).
Next we give our approach for estimating multivariate FPCA based on properties given
in section 3 of Happ & Greven. [69].
1. For each element X (j) , j = 1, · · · , p, estimate univariate FPCA based on observation
(j)
(j)
for N subjects, as a result, eigenfunctions φ̂m and FPC score ξˆi,m can be estimated.

Here, i = 1, · · · , N , m = 1, · · · , Mj is the truncation parameter of element X (j) .
2. Let M+ =

Pp

j=1

Mj , define matrix B ∈ RN ×M+ , each row of B is a vector of es-

timated FPC scores of subject i for p-dimensional functional covariates, Bi,. =
(1)
(1)
(p)
(p)
(ξˆi,1 , · · · , ξˆi,M1 , · · · , ξˆi,1 , · · · , ξˆi,Mp ). Hence we can get the estimated Z matrix,
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ẐM + ×M + = (N − 1)−1 B > B.
3. We then perform spectral decomposition of Ẑ matrix, resulting estimated eigenvalues (v̂1 , · · · , v̂m , · · · , v̂M+ ) and eigenvectors (ĉ1 , · · · , ĉm , · · · , ĉM+ ).
4. Estimation of multivariate eigenfunctions are given as follows:

(j)
ψ̂m
(t)

Mj
X
(j)
=
[ĉm ](j)
n φ̂n (t),
n=1

(j)

here [ĉm ]n is the nth(n = 1, · · · , Mj ) element of jth(j = 1, · · · , p) block of eigen(j)

vector ĉm (m = 1, · · · , M+ ), φ̂n (t) is the univariate FPC eigenfunction obtained
from step 1. Multivariate FPC scores for each observation can also be calculated
using following formula:

ρ̂i,m =

Mj
P X
X

(j)

ˆ
[ĉm ](j)
n ξi,n = Bi,. ĉm ,

j=1 n=1
(j)
here i = 1, · · · , N , m = 1, · · · , M+ , ξˆi,n is the estimated univariate FPC score

obtained from step 1. Therefore, we are able to express multivariate functional
covariates for subject i as Xi (t) in terms of estimated multivariate eigenfunctions
and scores,

(1)

(p)

Xi (t) = (Xi (t), · · · , Xi (t)) =

M+
X
m=1
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(1)
ρ̂i,m ψ̂m
(t), · · · ,

M+
X
m=1

!
(p)
ρ̂i,m ψ̂m
(t) .

(3.1)

Following the theory foundation in aforementioned sections, we are able to estimate the
MFPC scores, which is included in the proposed Cox regression model 1 to integrate
multivariate longitudinal information.

3.3.2

Longitudinal marker selection

As PPMI study collected many longitudinal markers of participants during follow up period, we first investigate the prediction ability of each candidate markers in order to select
appropriate markers in disease progression prognostic model. Joint modeling method is
employed to simultaneously model time to reaching H&Y stage 3 and candidate longitudinal markers, and assess the association strength of each markers and survival outcome
[28, 70]. The joint model consists of two sub-models, one is the linear mixed-effects
model for longitudinal data, another is the Cox regression model for survival data. The
time metric for both models is years from enrollment. As the intention is to assess the
prognostic ability of different markers, we standardize each longitudinal outcome before
fitting the model to make them comparable. The association parameter from the fitted
joint model is used to capture the relation between longitudinal marker and survival outcome, which in our case, quantifies the prediction ability of time to disease progression
for candidate markers. An significant estimation of association parameter meant that the
marker accounts for the variation of time to H&Y stage transition to 3. In all models, we
control for baseline covariates: gender, race, age, education years, years of PD diagnosis
and handedness. The joint modelling results are presented in Table 3.2, with longitudi59

nal markers ranked by the absolute value of association parameter’s Z-score. Candidate
markers ranked within top 5 are selected to be the longitudinal predictor included in
our proposed prognostic model, i.e., MDS-UPDRS 3, MDS-UPDRS 2, QUIP, SDM, and
SCOPA-AUT.

Longitudinal

N

Association

marker

P-value

Z-Score

(SE)

MDS-UPDRS 3

417

1.124(0.011)

<0.001

6.413

MDS-UPDRS 2

417

0.730(0.007)

<0.001

5.577

QUIP

410

-3.026(0.162)

<0.001

-3.226

SDM

410

-0.378(0.004)

0.002

-3.164

SCOPA-AUT

410

0.328(0.008)

0.007

2.715

SEADL

417

-0.361(0.009)

0.025

-2.279

MDS-UPDRS 1

417

0.309(0.009)

0.031

2.120

MoCA

417

-0.244(0.006)

0.060

-1.973

Derived LNS

410

-0.201(0.005)

0.140

-1.455

GDS15

410

0.106(0.008)

0.476

0.715

Semantic Fluency

410

0.031(0.009)

0.856

0.172

Table 3.2: Prediction of time to H&Y stage reaching 3 using longitudinal marker: joint
modelling results.
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3.3.3

MFPCA based Cox regression model

To predict the time to reaching H&Y stage 3, we specify our proposed Cox regression
model integrating the longitudinal information from selected 5 markers by extracting
features using MFPCA method (referred as Model 1). To ensure at least 99% of total
variation is explained, we select the first 10 MFPC scores as the extracted features of
those 5 longitudinal markers. For comparison purpose, we also specify another Cox
regression model with only subject’s demographic variables and baseline measurements
of selected 5 markers (referred as Model 2). Comparing the prediction performance of
these two models help us assess the gain from incorporating longitudinal information.
Before conducting the analysis, we fit a separate Cox model to select significant baseline
demographic variables, age, gender, baseline t-tau, and baseline Aβ1−41 are identified as
significant predictors. Due to the fact that the exact date of patient transit to H&Y
stage 3 is unknown, we define the time to event outcome as time to the first visit that
patient was rated as H&Y stage 3 while subjects who did not reach H&Y stage 3 yet are
considered as censored. Controlling for common baseline variables, we specify the hazard
function for Model 1 (Equation 1) and Model 2 (Equation 2) as following:
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hi (t) = h0 (t) exp{β1 Agei + β2 Malei + β3 t-taui + β4 Aβi +

10
X

αk MFPCscoresik }

(3.2)

k=1

hi (t) = h0 (t) exp{β1 Agei + β2 Malei + β3 t-taui + β4 Aβi + β5 MDS-UPDRS3i
(3.3)
+ β6 MDS-UPDRS2i + β7 QUIPi + β8 SDMi + β9 SCOPA-AUTi }.
Here, h0 (t) represents the baseline hazard function, β denotes the coefficients associated
with risk factors, and α denotes the regression coefficients for MFPC scores. To ensure
we have sufficient observations for each longitudinal markers to calculate MFPC scores,
we exclude subjects only have less or equal than two available longitudinal measurements
for any of the markers.
We assess the prediction performance of the previous specified models from two aspect.
To assess the global discrimination ability, we employ the integrated area under the
time-dependent receiver operating characteristic curve (iAUC) proposed by Uno et al
[71], which is based on inverse-probability-of-censoring weights. On the other hand, we
evaluate the calibration ability of prognostic models by integrated Brier score (BS) [72].
Moreover, while iAUC and BS are well studied in quantifying the overall prediction
performance, comparing the time-dependent AUC between the two pre-specified models
is also important. We employ the methodology approach proposed by Blanche et al [73]
to compute confidence region of time-dependent AUC and test for the difference between
them in the two aforementioned prognostic models. Regards of prediction, we use 10-
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fold cross validation (CV) strategy to avoid overestimation. We repeatedly conduct
CV in PPMI dataset for 100 times using different random seed to reduce the variation
caused by data splitting. The internal iAUC and BS for both models are calculated
to assess the improvement when integrating longitudinal information in prognostication,
and the confidence region of difference of time-dependent AUC from the two models is
calculated to test for significance. With the intention to establish an index that can
be used across studies, we computed the prognostic index (PI) from the MFPCA based
Cox regression Model 2. The formula for calculating prognostic index is based on the
estimated regression coefficients:

PI = β1 Agei + β2 Malei + β3 t-taui + β4 Aβi +

10
X

αk MFPCscoresik .

(3.4)

k=1

We use data from LABS-PD to conduct external validation. Since LABS-PD did not
collected all the top 5 ranked longitudinal markers in PPMI (MDS-UPDRS 3, MDSUPDRS 2, QUIP, SDM, and SCOPA-AUT), we rank the available markers in both studies
by their absolute Z-score and select the top 5 to be included in validation prognostic
models, i.e., MDS-UPDRS 3, MDS-UPDRS 2, MDS-UPDRS 1, SEADL, MDS-UPDRS
1, MoCA. In external validation session, we refer the two Cox regression models as The
Model 1a and Model 2a, which are similar to Equation 1 and Equation 2 respectively,
with the only difference that instead of using the optimal 5 longitudinal markers, we use
the 5 top ranked markers among available ones in both studies. We exclude the subjects
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who only measured less or equal than twice for any of these longitudinal markers during
follow up. To better compare the prediction performance of proposed models across
studies, we first conduct internal validation for Model 1a and Model 2a in PPMI and
LABS-PD separately. The external validation is conducted by applying models fitted
from PPMI data on LABS-PD data. Prediction performance is evaluated by iAUC and
BS. Based on the Model 2a fitted in PPMI data, we establish the formula for calculating
prognostic index using regression coefficients. We then apply the formula on LABS-PD
data to assess the ability of categorizing risk groups across studies.

3.4

PPMI Study Application Results

The results of the prognostic models are summarized in Table 3.3. While the the internal
prediction performance index (iAUCIN T ) for baseline Cox regression Model 2 on PPMI
is 0.758, the internal iAUC for MFPCA based Cox regression Model 1 gets 5 percentage
point higher by incorporating longitudinal information of selected markers. Similarly, the
internal Brier Score (BSIN T ) for Model 1 is 0.094, which is about 1 percentage point lower
than Model 2, indicating the bias between predicted and true risk is smaller in Model
1. To illustrate the comparison results, we plot the estimated time-dependent AUC of
MFPCA model (Model 1) and Baseline Model (Model 2) as well as the difference of mean
AUC from these two prognostic models in Figure 3.1. From the AUC plot (left panel), We
find that the estimated time-dependent AUC is higher for MFPCA model when compared
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to Baseline model at all landmark time. Moreover, the right panel shows the difference of
mean AUC is alway above 0 across time, and the confidence interval does not contain 0
after around 40 months, indicating the AUC difference between two prognostic models is
significant when in later prediction time. As the analysis results favor Model 1 in regards
of higher iAUC and lower BS, we select Model 1 to establish the prognostic index. Based
on the regression coefficients estimated from Model 1, we follow formula in Equation (3)
to calculate PI for each subject in PPMI. We then use the PI quartiles (50%, 75%, 100%)
to categorize subjects into three risk groups (high, mid and low). For comparison purpose,
we also calculate a similar prognostic risk score based on Model 2 and classify subjects into
different risk groups according to calculated risk scores. The Kaplan-Meier (K-M) curves
for PD progression risk groups categorized from two prognostic models are presented in
Figure 3.2. Comparing the Kaplan-Meier curves for the 3 risk groups classified according
to PI from Model 1 (left panel) and the curves for risk groups classified based on Model 2
(right panel), we find PI quartiles from Model 1 separate risk groups better in the sense
of non over-lapping survival probability confidence band in later follow-up time, which
agrees with the difference of estimated AUC plot in Figure 3.1. The finding suggests
that incorporating longitudinal information in prognostic model help to identify subjects
with higher risk of reaching H&Y stage 3 after enrollment. We then apply the proposed
prognostic models in LABS-PD to assess the prediction performance across studies. Due
to the availability of longitudinal markers in LABS-PD, we choose the 5 top ranked
markers that is collected in both PPMI and LABS-PD studies instead of using the optimal

65

5 longitudinal markers. The MFPCA based Cox regression model adjusted for data
availability is referred as Model 1a, and the corresponding prognostic model only includes
baseline measurements is referred as Model 2a. To establish a benchmark for comparison,
we conduct 10-fold class internal validation in PPMI and LABS-PD respectively, after
that the external validation is carried out in LABS-PD using models fitted in PPMI
dataset. Results for internal and external validation are summarized in Table 3.3. The
iAUC calculated from Model 1a, which includes the top 5 available markers, is 0.797,
about 1 percentage point lower than iAUC for Model 1 including optimal 5 markers.
When compared with the baseline Cox regression Model 2a, mean iAUC estimated from
Model 1a incorporating longitudinal information is about 5 percentage point higher. In
internal validation for LABS-PD study, iAUC for Model 1a is 0.806, which is about 8
percentage higher than Model 2a which only accounts for baseline measurements. For
external validation, we fit the proposed models in PPMI, and apply the prognostic models
on LABS-PD data. As a result, Model 1a is also favored with higher iAUC and lower BS.
The consistent internal and external findings suggests Model 1a has a better prognostic
ability regarding prediction of time to H&Y stage reach 3 across studies. When it comes
to the comparison between iAUC from internal and external validation in LABS-PD, we
find the iAUC of external validation is 8 percentage point lower in Model 1a, while the
difference is 2 percentage point in Model 2a. This could be caused by the nature of the
two studies. While PPMI only recruited early, untreated PD patients, the 537 subjects
in LABS-PD PostCEPT were part of participants from previous conducted PRECEPT
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study and not necessarily de-novo patients. Figure 3.3 shows the Kaplan-Meier plot for
the high, mid and low risk groups of PD progression in PPMI and LABS-PD respectively.
The risk curves for LABS-PD is similar to the curves for PPMI with the top curve for
low risk subjects, bottom curve for high risk group and the curve in the middle for mid
risk group. The plots indicate the PI formula established in PPMI can be well applied
to LABS-PD to classify subjects with different level of progression risk. Moreover, the
low risk group in LABS-PD study progresses faster than the same risk group in PPMI,
which is consist with the characteristic of LABS-PD subjects that they have longer PD
disease history than PPMI subjects and tend to progress in nearer future. With the
calculated PI, We are able to estimate the survival probability for subjects in different
risk groups based on the Kaplan-Meier curves in Figure 3.3 correspondingly. Also, with
the approximated baseline risk function (e.g. using piece-wise constant or splines) we are
able to calculate the survival risk of time to H&Y stage reaching 3 for specific subject.

67

Study
PPMI (n=375)
LABS-PD (n=459)

PPMI (n=375)
LABS-PD (n=459)

Model 1

Model 2

Model 1a

Model 2a

iAUCIN T

iAUCIN T

iAUCIN T

iAUCEXT

iAUCIN T

iAUCEXT

0.808

0.758

0.797

-

0.752

-

-

-

0.806

0.720

0.721

0.701

BSIN T

BSIN T

BSIN T

BSEXT

BSIN T

BSEXT

0.094

0.106

0.089

-

0.097

-

-

-

0.184

0.165

0.292

0.172

Table 3.3: Comparison of prognostic models in internal validation and external validation. Model 1 is the proposed prognostic model with optimal 5 markers, Model 2 is the
corresponding baseline prognostic model. Model 1a and Model 2a are similar models
with top 5 ranked available markers.

(a) Estimated AUC plot over time

(b) Difference of estimated AUC plot over time

Figure 3.1: Time-dependent AUC plot for Model 1 and Model 2.
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(a) Risk groups categorized based on Model 1 (b) Risk groups categorized based on Model 2

Figure 3.2: Kaplan-Meier plot for risk groups of PD progression to H&Y stage 3.

(a) Kaplan-Meier plot for subjects in PPMI (b) Kaplan-Meier plot for subjects in LABS-PD

Figure 3.3: Kaplan-Meier plot for risk groups of PD progression to H&Y stage 3 in PPMI
and LABS-PD.
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Chapter 4

Article 3: Dynamic prediction of recurrent events
using multiple longitudinal outcomes
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Dynamic prediction of recurrent events using multiple
longitudinal outcomes

4.1

Introduction

Over the past decades, the prevalence of cardiovascular disease (CVD) has motivated
systematic investigation into its risk factors, prevention strategy and treatment method.
As the first large CVD study with longitudinal follow up visits, Framingham Heart Study
(FHS) has been collecting longitudinal clinical outcomes at each schduled exam since 1948
[74]. Due to the emerging evidence of the role of shared familial factors in developing
CVD, researchers are interested in study the next generation of participants. FHS investigators recruited the Offspring Cohort, which consists of a group of children of Original
Cohort members with coronary disease and the spouses of those children [75]. Starting
from 1972, the FHS Offspring Cohort conducted in-person examinations for participants
to collect longitudinal measurements including systolic blood pressure (SBP), body mass
index (BMI), blood glucose and etc. Although there are numerous literature aiming at
identifying risk factors for CVD, a growing interest lay in the prediction of the occurrence
of cardiovascular events. As the primary outcome of FHS Offspring Cohort is the CVD
events, which have feature of recurrence (i.e. the event of interest often occurs multiple

71

times from the same subject), the commonly used Cox proportional hazard model will
not be appropriate, since it ignores the intrinsic correlation between those repeated occurrences within the same subject [21]. To avoid the biased estimated risk, proposing an
effective prediction model for the next-occurrence of CVD event is of importance here.
Moreover, as the recurrent CVD events tend to have significant association with clinical longitudinal markers, incorporating those rich longitudinal information in prediction
models meets the urgent need of improving the prognostic performance. A few of studies
has investigated joint analysis of longitudinal marker and recurrent event [28, 32, 36,
37], however, utilizing information from multiple longitudinal markers to predict the risk
of re-occurrence of events remains an open question. Motivated by the FHS Offspring
data, our study focuses on the joint analysis of multiple longitudinal clinical markers and
recurrent CVD events. A prediction model is proposed to estimate the risk of having
another recurrent CVD event in given time interval. Moreover, we develop a dynamic
prediction framework for the next occurrence of CVD event using subject-specific longitudinal profiles, which enables physicians give personalized and precision treatment to
patients.
Joint models (JM) of longitudinal measurements and survival data (including terminal event and recurrent event data) have been a popular method to analyze clinical
measurements and event of interest together in the past decades. Among the existing
literature, Henderson [28] proposed a joint model of longitudinal data and recurrent event
data, with association between two process captured by correlated latent trajectory. Liu
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and Huang [32] established a JM approach where a more complex setting was considered, i.e. a repeated measures process and a recurrent events process were correlated,
both subject to a terminal event. In terms of prediction of terminal event risk under JM
framework, Krol et al [36] extended the usage of joint model of longitudinal data, recurrent events, and a terminal event to dynamic prediction area. As a result of their work,
the probability of having a terminal event in specific time interval is estimated, given
previous longitudinal profile and recurrent event history. In recurrent events prediction
area, Musoro et al [37] employed landmark method to handle the longitudinal data as
time-fixed covariate at different landmark time point, and in this way extended dynamic
prediction by landmarking to recurrent event data. However, these publications only
investigated the prediction ability of single longitudinal outcome. While it is challenging to specify appropriate parameter distributions when modelling multiple longitudinal
trajectories, the major limitation occurs in extending the JM approach to incorporate
multivariate longitudinal outcomes. In addition to the issue in statistical aspect, the computation intensity becomes another concern when joint model under Bayesian framework
is considered, especially with a large number of candidate longitudinal markers.
To avoid involving in the potential issues when extending JM framework, we consider a novel approach which is more flexible, robust and time efficient. Since Yao [38]
proposed a nonparametric approach to perform functional principal components analysis
(FPCA) on sparse longitudinal data, researchers has extended the usage of FPCA to
joint analysis of repeated measurements and survival data [39]. In the two-step approach
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proposed by Holte et al [40], the feature of longitudinal trajectory was extracted and
represented by the functional principle component (FPC) scores estimated from separate
model, and the estimated FPC scores were included in the survival model as new risk
factors to build association between longitudinal trajectory and the survival outcome.
Yan et a [41] extended the FPCA framework further to dynamic prediction area, their
work enables the estimated FPCA scores can be updated as new longitudinal information
come into available. However, these studies focused only incorporating information from
single longitudinal marker in the survival model, moreover, the Cox model they used to
model the terminal event is not suitable when the event of interest has recurrent feature
(e.g. CVD events). To our best knowledge, no existing literature has investigated the
prediction of recurrent event utilizing information from multiple longitudinal markers.
In this article, we develop an novel approach to fit this critical need. In the proposed approach, we first extract the feature of multiple longitudinal trajectories using multivariate
FPCA (MFPCA) method, and then fit a recurrent event model with intensity function
incorporating the feature scores from longitudinal markers. The dynamic prediction for
the risk of next occurrence of recurrent event is also derived to conduct personalized
prediction based on subject-specific longitudinal measurements.
The rest of the article is organized as follows. In Section 2, we illustrate the modeling
framework with detailed description of MFPCA method that used to extract features of
longitudinal outcomes, the recurrent event model with Poission intensity function, and
the dynamic prediction derivation. In Section 3, the proposed approach is applied on
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the motivating FHS Offspring Cohort, and the estimated AUC is compared across candidate models. The simulation results are presented in Section 4 to assess the prediction
performance of our proposed model under different scenarios. In the last section, the
concluding remarks and future research directions are discussed.

4.2

Methods

In this section, we give a detailed description of the proposed approach to model the
recurrent CVD events incorporating information from multiple longitudinal outcomes.
Considering a study of N subjects. Let {Yijq } = {Yiq (tij )} be the vector of longitudinal
observation of the q-th (q = 1, · · · , Q) clinical marker for subject i at time tij , where
i = 1, . . . , N , and j = 1, . . . , mi . Assuming there exists an underlying latent trajectory
Xiq (t) for each observed longitudinal measurement Yiq , we denote the corresponding error
term as ijq and re-write the longitudinal observation as Yij (tij ) = Xiq (tij ) + ijq , where
epsilonijq has zero mean and variance σ2q . Let Tik be the recurrent event times from
study onset for subject i, k = 0, . . . , ni , where ni denotes the total number of recurrent
CVD events subject i experienced.

4.2.1

multivariate FPCA method and implement

Let X i (t) denote the vector that combined q different functions, i.e, X i (t) = (Xi1 (t), · · · ,
Xiq (t), · · · , XiQ (t)), where q = 1, · · · , Q. Before getting into multivariate FPCA, We
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first illustrate univariate FPCA method for single longitudinal outcome q. We denote
the smoothed mean function of Xiq (t) as µq (t), and the covariance function which models correlation of longitudinal outcome q’s latent trajectory between time t and t0 as
Σq (t, t0 ) = cov{Xiq (t), Xiq (t0 )}. Using spectral decomposition, the covariance function can
0
be re-write as Σq (t, t0 ) = Σ∞
n=1 λqn φqn (t)φqn (t ), with {λqn } represent the non-increasing

eigenvalues for outcome q, and {φqn (t)} denote the corresponding eigenfunctions. The
Karhunen-Loéve theory give a representation of Xiq (t) as:

Xiq (t) = µq (t) +

∞
X

ξiqn φqn (t).

(4.1)

n=1

Here, {ξiqn } is the set of uncorrelated FPC scores with 0 mean and variance λqn . The
FPC scores describes how the observed profile of subject i follows the changing pattern
φqn (t), and can be viewed as the extracted feature of subject i. Moreover, the latent
trajectory can be approximated with finite terms as Xiq (t) ≈ µq (t) +

PNq

n=1 ξiqn φqn (t),

where Nq can be selected according to pre-specified percentage of variance explained
(PVE). As the actual observed longitudinal data for outcome q is usually only available
for irregular visit time and tend to be sparse data, we employ the principle analysis by
conditional estimation (PACE) [38] to conduct analysis. We can express the longitudinal
observation Yijq as:

Yijq = Xiq (tij ) + ijq = µq (tij ) +

Nq
X
n=1
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ξiqn φn (tij ) + ijq .

(4.2)

The PACE method was demonstrated to be powerful when applied to sparse longitudinal
data with noise. We use it to estimate the mean function µq (tij ), covariance function
Σiq (t, t0 ), eigenfunctions {φqn } and FPCA scores ξ iqn , where n = 1, · · · , Nq . Basically,
the estimated mean function µ̂q (tij ) is obtained by a one-dimensional kernel smoother.
Following the estimation of mean function, the covariance matrix Σ̂ can be estimated by
a two-dimensional kernel smoother with pairwise products {Yijq − µˆq (tij )}{Yilq − µˆq (til )}.
Thus we are able to obtain eigenfunctions φ̂qn and eigenvalues λ̂qn , n = 1, · · · , Nq ,
by spectral decomposition of covariance matrix Σ̂iq . Based on the estimation results,
the FPCA scores for longitudinal trajectory of subject i can be estimated based on its
conditional expectation, specifically:

0

ξˆiqn = Ê(ξiqn |Yiq ) = λ̂qn φ̂qn Σ̂−1
Yiq (Y iq − µ̂q ).

(4.3)

Since the estimated FPC scores from q longitudinal clinical outcomes can be correlated
due to their intrinsic relationship, we use MFPCA method to extract features of multiple
longitudinal outcomes while capturing the joint variation between different outcomes [69].
Let M+ =

PQ

q=1

Nq , define matrix B ∈ RN ×M+ , each row of B is a vector of estimated

FPC scores of subject i for q-th outcome, Bi,. = (ξˆi11 , · · · , ξˆi1Nq , · · · , ξˆiQ1 , · · · , ξˆiQNQ ).
Hence we can get the estimated Z matrix, ẐM + ×M + = (N − 1)−1 B > B. We then perform spectral decomposition of Ẑ matrix, resulting estimated eigenvalues (v̂1 , · · · , v̂m ,
· · · , v̂M+ ) and eigenvectors (ĉ1 , · · · , ĉm , · · · , ĉM+ ). Estimation of multivariate eigenfunc-
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tions are given as ψ̂mq (t) =

PNq

n=1 [ĉm ]nq φ̂nq (t),

here [ĉm ]nq is the nth(n = 1, · · · , Nq )

element of q-th(q = 1, · · · , Q) block of eigenvector ĉm (m = 1, · · · , M+ ), φ̂nq (t) is the
univariate FPC eigenfunction obtained from training dataset. Multivariate functional
principle component (MFPC) scores for each observation can also be calculated using
following formula:
ρ̂im =

Q Nq
X
X

[ĉm ]nq ξˆiqn = Bi,. ĉm ,

(4.4)

q=1 n=1

here m = 1, · · · , M+ , ξˆiqn is the estimated univariate FPC score obtained from step 1.
We select first D ≤ M + FPC scores based on pre-specified PVE or other criterion such as
Akaike information criterion (AIC) to represent the features extracted from multivariate
longitudinal trajectories, and use them in the recurrent event model. Therefore, we are
able to express the underlying trajectories of q-th longitudinal outcome for subject i in
terms of estimated multivariate eigenfunctions and scores:

Xiq (t) ≈ µˆq (t) + ΣD
m=1 ρ̂im ψ̂qm (t)

4.2.2

(4.5)

Recurrent event model

Assuming that the number of recurrent events in non-overlapping time intervals is a
poisson process, we are able to model the event process via intensity function. To inˆ im
tegrate multivariate longitudinal information, we use the estimated MFPC scores rho
as predictors in the intensity function, to model the relationship between longitudinal

78

outcomes and recurrent events. Following previous notation, the intensity function of
recurrent events for subject i is:

ri (t) = r0 (t) exp{Z R
i β + ρ̂i γ + vi }.

(4.6)

Here, the covariate vector Z R
i is the time-independent covariates and β is the corresponding coefficient vector, γ is the vector of coefficient for the estimated MFPC scores {ρ̂im },
m = 1, · · · , D, vi is the random effect follows normal distribution N (0, σv ). We utilize
piece-wise constant baseline hazard model to obtain estimators for both fixed effects and
random effects, which increase the robustness of our model fitting. The total follow-up
time interval [0, τ ] is divided using time knots τt = (0, τ1 , ..., τR ) by quantile of event
times, and the baseline hazard vector is denoted as g = (g0 , g1 , ..., gR−1 ). Then we can
define the piecewise constant hazard function as h0 (t) =

PR−1
r=0

gr Ir (t), where indicator

function Ir (t) = 1, if τr ≤ t < τr+1 and 0 if otherwise. Therefore, conditioning on random
effect vi , the likelihood of the recurrent events process for subject i is:

liR

=
=

ni
Y

ri (tik )σik Si (xi )

k=0
ni 
Y

r0 (tik ) exp



ZR
i β

δik



Z

· exp −

+ ρ̂i γ + vi

r0 (t) exp
0

k=0
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τi



ZR
i β


+ ρ̂i γ + vi dt ,

where δik is the indicator of a recurrent event at time tik and τi is the observed follow-up
time. Thus, the full likelihood for subject i is

li = liR · f (vi ),

(4.7)

where f (vi ) is the density function of vi . The unknown parameter vector is θ = {β, γ, σv , r0 (t)}.

4.2.3

Dynamic prediction

In order to extend the proposed model framework to dynamic prediction of event risk,
we randomly partition the dataset into two part, one is the training datasest which is
used to build the model, another is the validation dataset to access the prediction performance of proposed model. We first apply our proposed MFPCA approach on training
dataset and estimate parameters and MFPC scores ρ̂m using all available longitudinal
observations. With the estimated MFPC scores and time-independent covariates, we fit
recurrent event model (4.6) in training dataset. After obtaining the estimated parameter
vectors β̂, γ̂, r̂0 (t), we then illstrate the derivation and procedure to conduct prediction
in validation dataset. Suppose a new subject L had nL (e.g., nL = 0, 1, 2, · · · ) recurrent events up to time t, with q longitudinal outcomes Y Lq = {YLq (tLj ); 0 ≤ tLj ≤ t},
we fist compute the FPC scores for the q-th outcome using equation (4.3), specifically,
0

ξLqn = λ̂qn φ̂qn Σ̂−1
YLq (Y Lq − µ̂q ). With the estimated FPC scores for each of the longitudinal
outcomes, We then compute the MFPC scores ρ̂L for subject L following equation (4.5).
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Our goal is to predict his/her probability of having the nL + 1 recurrent event before time
t0 = t + ∆t (e.g., 1 year), denoted by πL (t0 |t) = P (TL,nL +1 ≤ t0 |TL,nL +1 > t, Z L , ρ̂L , θ).
The probability πL (t0 |t) can be derived as follows:

πL (t0 |t)
Z
= P (TL,nL +1 ≤ t0 |TL,nL +1 > t, Z L , ρ̂L , θ, vL )P (vL |TL,nL +1 > t, θ)dvL

(4.8)


 Z t0
M
1 X
(m)
(m)
(m)
rL (s|vL , Z L , ρ̂L , θ )ds .
1 − exp −
≈
M m=1
t
When new information come into available, the estimated prediction probability πL (t0 |t)
can be updated, which leads to dynamic risk prediction that change over time when
more data accumulate. We first update the estimated MFPC scores ρ̂L using enriched
multivariate longitudinal information. The updated MFPC scores reflect the trends that
altered by new observations. Then we update the estimated recurrent event risk. Here
θ (m) is the mth sample (m = 1, . . . , M , where M is the number of post burn-in samples)
(m)

of parameter vector θ. For random effect, v L

(m)

is the mth sample of v L . The term rL

denotes the intensity function from poission process conditioning on mth copy of θ and
0

corresponding random effect v L . To approximate the event probability πL (t |t), we need
to obtaining samples for random effect v L . The posterior samples of vL is drew from its
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posterior distribution P (vL |TL,nL +1 > t, θ) as follows:

P (vL |TL,nL +1 > t, θ (m) ) =

P (TL,nL +1 > t, vL |θ (m) )
∝ P (TL,nL +1 > t, vL |θ (m) )
P (TL,nL +1 > t|θ (m) )

= P (TL,nL +1 > t|vL , θ (m) )P (vL |θ (m) ),

It is important to access how well our proposed risk prediction model performs. Here, we
access the prediction performance in terms of global discrimination ability. To be more
specific, we employ receiver operating characteristic (ROC) curve and the area under the
ROC curves (AUC) to assess the discrimination ability of the proposed model. Following
the definition in previous section, for a given cut value c ∈ [0, 1], the time dependent
sensitivity and specificity are P {πi (t0 |t) > c|D(t, t0 ) = 1, Ti∗ > t} and P {πi (t0 |t) ≤
c|D(t, t0 ) = 0, Ti∗ > t} respectively, where D(t, t0 ) is an indicator function equals to 1
when a new event happen during time interval (t,t’] and equals to 0 otherwise. Therefore,
0

0

0

for probability p ∈ [0, 1], the ROC curves will be ROCtt (p) = T Ptt [F Ptt ]−1 (p), where
0

0

T Ptt denotes the true positive rate, F Ptt denotes the false positive rate [56]. With the
defined time-dependent sensitivity and specificity, we calculate a standard “concordance”
summary: the time-dependent Area Under Curve (AUC) [57], the formula is AU C(t, t0 ) =
R1
0

0

ROCtt (p)dp.
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4.3

Application to FHS Offspring Cohort

In this section, we apply the proposed dynamic prediction approach to the motivating
Framingham Offspring Cohort. The primary survival outcome of FHS is the recurrent
general cardiovascular disease event. Scheduled every 4 year, investigators of FHS Offspring Cohort conducted exam on study participants, during which multiple longitudinal
clinical markers were measured. The whole follow-up period is from year 1972 to year
2015 with total 9 exams. Our primary goal is to assess the prediction performance of
combined multiple longitudinal outcomes on recurrent CVD events. Among the available clinical markers, we select the markers that are longitudinal collected and measured
at every exam. Specifically, we include 6 longitudinal clinical outcomes in the analysis:
systolic blood pressure (SBP), body mass index (BMI), blood glucose (BG), high-density
lipoprotein (HDL), total cholesterol (TC), triglycerides (TG). Evidence in previous related studies has shown significant correlation between these markers and CVD events
[76–80]. We also include other relevant time-independent covariates, i.e., age (in year),
gender (0 if female, 1 if male), diabetes (0 if no, 1 if yes) and smoking status (0 if no, 1 if
yes). After removing incomplete observations with missing data, our analysis focuses on
4221 participants in FHS Offspring Cohort. In the study, the participants were assessed
during each exam cycle, and had up to 9 longitudinal observations. As the exact date for
conducting exam varies across participants, we refer the average mean visit time for each
exam as the corresponding exam time. Among the participants, 734 subjects experienced
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1 general CVD events, and 801 subjects experienced more than 1 events, while the rest of
the participants are cardiovascular disease events free until the end of follow-up period.
We specify the intensity function of our proposed recurrent event model integrating the
multivariate longitudinal information in Model 1. In order to ensure at least 99% of total
variation is explained, we select the first 10 MFPC scores as the extracted features of
those 6 longitudinal markers. To compare the prediction performance of our proposed
model with other candidate models, we also specify another simple recurrent event model
with only subject’s time-independent covariates and baseline measurements of 6 longitudinal outcomes (referred as Model 2). Moreover, to test whether incorporating multiple
longitudinal information can improve the prediction ability on recurrent event data, we
apply the joint model of single longitudinal outcome (SBP, one of the most relevant clinical marker with CVD events) and recurrent event data (referred as Model 3) on FHS
Offspring dataset and compare it with our proposed approach. While controlling for
common baseline variables, we specify the intensity function for Model 1 as:

ri (t) = r0 (t) exp{β1 Agei + β2 Malei + β3 Smokei +

10
X

αk MFPCscoresik + vi },

(4.9)

k=1

and Model 2 as:

ri (t) = r0 (t) exp{β1 Agei + β2 Malei + β3 Smokei + β4 SBPi + β5 BMIi
(4.10)
+ β6 BGi + β7 HDLi + β8 TCi + β9 TGi + vi }.
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The Model 3 specification is as following:

SBPi (t) = γ0 + γ1 Agei + γ2 t + ui + ei (t) = fi (t) + ei (t)

(4.11)

ri (t) = r0 (t) exp{β1 Agei + β2 Malei + β3 Smokei + νfi (t) + vi }.
Here, r0 (t) represents the baseline intensity function, β denotes the coefficients associated with risk factors, and α denotes the regression coefficients for MFPC scores. In the
joint model, ui denotes the random effect in longitudinal process, and ν is the association
parameter. Subjects with less or equal than two available longitudinal measurements for
any of the markers are excluded while estimating MFPC scores. The prediction performance of the previous specified models are assessed by calculating the time-dependent
Area Under Curve (AUC) at different prediction starting point over the follow-up period. The 10-fold cross validation is conducted to avoid overestimation of the prediction.
The values of time-dependent AUC calculated based on the three candidate model are
presented in Table 4.1. From the summarized results, we find both three models have acceptable AUCs indicating a good prediction performance. Among the three models, our
proposed Model 1 has better prediction performance in regards of highest AUC for each
prediction time interval. The AUCs estimated from Model 1 have about 0.05 increase on
average when compared to Model 2 while the differences become larger in later prediction
time such as Exam 6 and Exam 7. This pattern indicates incorporating longitudinal information in prediction of recurrent CVD events will enhance the accuracy of predicting
risk of events, especially when prediction start at later follow-up time. When comparing
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T (year)

13 (Exam 3)

16 (Exam 4)

20 (Exam 5)

24 (Exam 6)
34 (Exam 7)

0

T (year)
16
20
24
26
34
38
20
24
26
34
38
24
26
34
38
26
34
38
34
38

Model 1
AUC
0.756
0.801
0.793
0.791
0.744
0.769
0.842
0.805
0.791
0.741
0.763
0.756
0.762
0.733
0.754
0.796
0.715
0.736
0.720
0.737

Model 2 Model 3
AUC
AUC
0.717
0.733
0.765
0.781
0.754
0.762
0.759
0.768
0.733
0.741
0.768
0.761
0.799
0.807
0.745
0.762
0.745
0.767
0.734
0.739
0.727
0.740
0.731
0.742
0.752
0.759
0.728
0.730
0.733
0.744
0.720
0.742
0.661
0.678
0.701
0.713
0.695
0.705
0.725
0.729

Table 4.1: Time-dependent AUC for Model 1 and candidate Model 2 & 3. Model 1 is the
proposed model based on MFPCA method, Model 2 is the baseline model, and Model 3
is the joint model with single longitudinal marker.
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Model 1 and Model 3, we notice an average of 0.03 increase in AUCs for our proposed
Model 1, suggesting the gain of prediction accuracy when include multivariate longitudinal information instead of considering single longitudinal outcome. As a result, we select
Model 1 as our final model and conduct dynamic prediction in the validation dataset. In
order to illustrate the personalized dynamic prediction, we select two subjects who have
different patterns of longitudinal profiles and experienced different occurrences of cardiovascular disease events. Conditioning on the available observations of 6 clinical markers,
we predict their longitudinal trajectory from different prediction starting time. Figure
4.1 and Figure 4.2 shows how the predictions of longitudinal outcomes are updated over
time for Subject 103 and Subject 122 respectively. From the left panel to the right panel
of these two figures, the predicted trajectories are closer to the true observed values, also,
the 95& confidence interval becomes more narrower, suggesting with more follow-up data
the prediction improves. In Figure 4.3, we present the predicted probability of developing
a new event in given time interval. Subject 103 did not experiance any CVD event during
the follow-up period, while subject 122 (lower panels) had 2 CVD events between Exam
3 and Exam 7. At the beginning of prediction, although both Subject 103 and subject
122 did not experience any CVD event, the estimated event-free probability of Subject
122 is lower than Subject 103, which consist with his/her worse longitudinal profiles (i.e.
significantly higher SBP, BMI, BG). The results suggest that Subject 122 has a higher
risk of developing re-occurrence CVD events and should be closely monitored.
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4.4

Simulation Study

In this section, we evaluate the performance of our proposed approach via simulation,
in which the simulated data mimic the application dataset. The primary goal of the
simulation study is to evaluate predictive performance of our proposed model under
different scenarios, and compare it with multivariate joint modelling approach. Focusing
on q longitudinal outcomes, q = 1, 2, 3, we use the linear mixed-effects models to generate
simulated longitudinal data, which is:

Yiq (t) = Xiq (t) + iq .

(4.12)

Here, Xiq (t) denotes the latent trajectory of the q-th longitudinal outcome, and iq is
the error term which follows normal distribution. Since in practise, the longitudinal
trajectories could follow different distributions, we consider three different scenarios of
latent trajectory Xiq (t) in the simulation:
1. Linear Model Xiq (tij ) = aq + bq1 Zi + bq2 tij + uiq
2. Exponential Model Xiq (tij ) = cq + exp(aq tij ) + uiq
3. Quadratic Model Xiq (tij ) = aq (tij − bq )2 + cq k + uiq
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Let ri (t) denote the intensity of the recurrent process, we then assume the recurrent event
intensity function of subject i as:

ri (t) = r0 (t) exp{z1 γ1 +

3
X

αq Xiq (t) + vi }.

(4.13)

q=1

We assume non-informative censoring for recurrent event process, the censoring time
Ci is sampled from uniform distribution with 50% censoring rate. Let Tik be the kth
recurrent event times from study onset (time 0) for subject i, k = 0, . . . , ni , where ni
denotes the number of recurrent events. Here, αq represents the association parameter
between q-th longitudinal outcome and the recurrent event process. Random effect from
longitudinal outcomes is denoted by ui1 , ui2 and ui3 , we assume them follow multivariate
normal distribution with mean 0. The covariance matrix is denoted by Σu , with σ12 , σ22 , σ32
denote the variance for random effects ui1 , ui2 , ui3 respectively, and ρ12 , ρ23 , ρ13 represents
the correlation between the three random effects. On the other hand, vi is the random
variable only associated with recurrent process and independent of ui1 , ui2 and ui3 , we
assume that it follows a normal distribution with variance denoted by σv2 . For each of
the 200 simulated datasets, the total sample size is 600, with randomly selected 400 subjects as the training dataset and the remaining 200 subjects for validation dataset. On
average, there are 2 recurrent events per subject. In each scenario, we conduct the model
inference in the training dataset using our proposed model based on MFPCA method,
and the true joint model which is used to simulate the data. Moreover, since it is always
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Scenario

Linear Model

Exponential
Model

Quadratic
Model

T (year) T 0 (year)
2
4
4
2
5
4
2
6
4
2
4
4
2
5
4
2
6
4
2
4
4
2
5
4
2
6
4

MFPCA Model 1 True JM
AUC
AUC
0.737
0.756
0.752
0.761
0.756
0.759
0.753
0.763
0.778
0.788
0.782
0.792
0.775
0.780
0.781
0.785
0.798
0.810
0.802
0.813
0.809
0.815
0.812
0.820
0.721
0.741
0.725
0.745
0.742
0.754
0.738
0.749
0.761
0.770
0.759
0.768

Miss-specified JM
AUC
0.612
0.614
0.621
0.634
0.639
0.641
0.601
0.605
0.610
0.612
0.623
0.629
0.593
0.602
0.603
0.604
0.611
0.615

Table 4.2: Time-dependent AUC for 3 scenarios
challenging to specify appropriate distribution for longitudinal process in applications,
assessing the performance of joint model with miss-specified latent trajectories is also
worth investigation. After fitting the model, for each scenario, we conduct dynamic prediction for subjects in validation dataset using three methods: our proposed model, joint
model with true latent trajectories, and joint model with miss-specified latent trajectories. The time-dependent AUCs are calculated for different prediction time interval, and
serve as a criteria to evaluate prediction performance. Results for dynamic prediction in
validation dataset are presented in Table 4.2. The AUC here is the average of all AUC
calculated within given time interval for 200 simulation times. From the summarized
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results, although the our proposed model has an average of 0.01 lower AUC than the
joint model under true trajectories, it outperforms the joint model when the longitudinal
distributions are miss-specified in regards of an average of 0.15 higher AUC. The results
suggest that the MFPCA approach is more robust compared to JM approach when the
underlying latent trajectory for longitudinal process is unknown. Moreover, the computation cost for multivariate joint model of longitudinal markers and recurrent event is
significantly higher than using our proposed MFPCA approach, which makes it hard to
implement JM approach when application sample size is large. Overall, our proposed
method has a robust predictive performance, also significantly improve computation efficiency.

4.5

Discussion

We integrate longitudinal information from varies of clinical markers in predicting the
risk of next occurrence of recurrent event in this study. By employing multivariate functional principle component analysis method, we develop a novel two-step approach to
model recurrent cardiovascular disease events with the extracted feature from historical observations of multiple relevant longitudinal clinical markers. Without assuming
parametric distribution of longitudinal trajectories, the multivariate functional principle
components analysis is a robust way to deal with joint variations between clinical markers
and captures the feature of subjects. Among all available candidate markers, we select
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the optimal 6 markers that are frequently measured and has been demonstrated as risk
factors of cardiovascular disease events in previous literature. We specify three prediction
models, one is the recurrent event model with estimated MFPC scores capturing feature
of multivariate longitudinal trajectories, one is the baseline recurrent event model only
accounting for demographic characteristics and baseline measurements of selected markers, another is the joint model of single longitudinal marker (SBP) and recurrent CVD
event. The application results suggest that including the historical observations of multivariate longitudinal markers improves prediction performance of recurrent CVD events
when compared to only consider baseline covariates or single longitudinal outcome. In
addition, we conduct a simulation study to evaluate the performance of our proposed approach under different circumstances. The results indicates that the MFPCA approach
is more robust than the parametric multivariate joint model in regards of significantly
higher AUCs when the underlying longitudinal trajectories are miss-specified. One limitation of the proposed two-stage approach is that in order to estimate parameters of
MFPCA, we will need the subjects in training dataset to have more than two observations for each of the selected longitudinal markers to ensure estimation accuracy. When
the sample size is small, excluding subjects without sufficient longitudinal observations
may lead to non-universal useful outcome. Another limitation is that when modeling
the recurrent event, we treat death as non-informative censoring, which may ignore the
correlation between recurrent CVD events and death. We plan to extend the proposed
model to take death process into account while predicting future occurrence of recurrent

92

events in future research work. In summary, our study propose a novel approach to
conduct personalized prediction of risk of recurrent cardiovascular disease events with
multivariate longitudinal clinical markers, which helps physicians to closely monitor high
risk participants and give personalized health care.
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Figure 4.1: Predicted longitudinal trajectories for Subject 103. Dashed lines are the 2.5%
and 97.5% percentiles. The dotted vertical line represents the time of prediction T.
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Figure 4.2: Predicted longitudinal trajectories for Subject 122. Dashed lines are the 2.5%
and 97.5% percentiles. The dotted vertical line represents the time of prediction T.
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Figure 4.3: Predicted CVD event free probability for Subject 103 (upper panels) and
Subject 122 (lower panels) in ALLHAT study. Dashed lines are the 2.5% and 97.5%
percentiles.
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